CA3036646A1 - Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles - Google Patents
Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles Download PDFInfo
- Publication number
- CA3036646A1 CA3036646A1 CA3036646A CA3036646A CA3036646A1 CA 3036646 A1 CA3036646 A1 CA 3036646A1 CA 3036646 A CA3036646 A CA 3036646A CA 3036646 A CA3036646 A CA 3036646A CA 3036646 A1 CA3036646 A1 CA 3036646A1
- Authority
- CA
- Canada
- Prior art keywords
- particles
- less
- composition according
- approximately
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract description 359
- 230000009747 swallowing Effects 0.000 title claims abstract description 57
- 230000037406 food intake Effects 0.000 title claims abstract description 42
- 239000007787 solid Substances 0.000 title claims abstract description 23
- 239000008247 solid mixture Substances 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 131
- 210000003296 saliva Anatomy 0.000 claims abstract description 70
- 239000004480 active ingredient Substances 0.000 claims abstract description 53
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 239000008240 homogeneous mixture Substances 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 150000007524 organic acids Chemical class 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 18
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 17
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 16
- 239000004386 Erythritol Substances 0.000 claims description 15
- 235000019414 erythritol Nutrition 0.000 claims description 15
- 229940009714 erythritol Drugs 0.000 claims description 15
- 230000002641 glycemic effect Effects 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 229920005862 polyol Polymers 0.000 claims description 14
- 150000003077 polyols Chemical class 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 7
- 239000001354 calcium citrate Substances 0.000 claims description 7
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 50
- 238000012360 testing method Methods 0.000 description 39
- 210000000214 mouth Anatomy 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 25
- 238000007873 sieving Methods 0.000 description 21
- 239000006191 orally-disintegrating tablet Substances 0.000 description 20
- 239000003826 tablet Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 13
- -1 or more recently Substances 0.000 description 13
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 11
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 239000000600 sorbitol Substances 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 210000002200 mouth mucosa Anatomy 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000007757 hot melt coating Methods 0.000 description 5
- 229960001680 ibuprofen Drugs 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 240000001717 Vaccinium macrocarpon Species 0.000 description 4
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000004634 cranberry Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 240000007551 Boswellia serrata Species 0.000 description 3
- 235000012035 Boswellia serrata Nutrition 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 235000012311 Tagetes erecta Nutrition 0.000 description 3
- 240000000785 Tagetes erecta Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- MKXZASYAUGDDCJ-NJAFHUGGSA-N dextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-NJAFHUGGSA-N 0.000 description 2
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- 235000002780 gingerol Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001033 granulometry Methods 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- QTQPVLDZQVPLGV-UHFFFAOYSA-N oxomemazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3S(=O)(=O)C2=C1 QTQPVLDZQVPLGV-UHFFFAOYSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000001841 zingiber officinale Substances 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical compound NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- LREQLEBVOXIEOM-UHFFFAOYSA-N 6-amino-2-methyl-2-heptanol Chemical compound CC(N)CCCC(C)(C)O LREQLEBVOXIEOM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 235000008730 Ficus carica Nutrition 0.000 description 1
- 244000025361 Ficus carica Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical group C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000016911 Ribes sativum Nutrition 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 244000281209 Ribes triste Species 0.000 description 1
- 235000016897 Ribes triste Nutrition 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241001278097 Salix alba Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- YSIITVVESCNIPR-UHFFFAOYSA-N Troxipide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC2CNCCC2)=C1 YSIITVVESCNIPR-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229940023032 activated charcoal Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- ZPFXAOWNKLFJDN-UHFFFAOYSA-N alverine Chemical compound C=1C=CC=CC=1CCCN(CC)CCCC1=CC=CC=C1 ZPFXAOWNKLFJDN-UHFFFAOYSA-N 0.000 description 1
- 229960000845 alverine Drugs 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960001704 carbimazole Drugs 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960005402 heptaminol Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229930185824 macrocarpon Natural products 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001920 niclosamide Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229960003045 oxomemazine Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 229960005126 tapentadol Drugs 0.000 description 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- IQWYAQCHYZHJOS-UHFFFAOYSA-N tetrazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CCCCC1 IQWYAQCHYZHJOS-UHFFFAOYSA-N 0.000 description 1
- 229960005214 tetrazepam Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001341 troxipide Drugs 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000004108 vegetable carbon Substances 0.000 description 1
- 235000012712 vegetable carbon Nutrition 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, said composition comprising the following two different types of particles: particles Pa, with very low solubility in saliva and comprising at least one active ingredient, and particles Ps, with rapid solubilisation in saliva, characterised by a bulk density greater than or equal to approximately 0.6 g.cm-3, advantageously greater than or equal to approximately 0.7 g.cm-3, and preferably between 0.7 and 1.5 g.cm-3.
Description
Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles Technical field The present invention concerns the field of solid oral compositions, for pharmaceutical or nutritional purposes, suitable to be administered to a human or animal individual.
More particularly, the invention relates to a solid galenic form with rapid ingestion and facilitated swallowing.
State of the art Solid oral compositions (such as in particular medicines or food supplements/
nutritional compositions) generally come in the form of capsules or tablets.
One of the main problems posed by oral administration of solid forms such as tablets or capsules is swallowing. Indeed, approximately 35% of people in the median age group of the population suffer from dysphagia problems and struggle to swallow tablets or capsules. This percentage is significantly greater among young children and the elderly, not to mention mentally impaired or medically uncooperative persons. Such difficulties are a considerable factor in the poor compliance - or non-compliance - with treatments (in particular for long-term treatments).
In response to this problem, pharmaceutical compositions have been developed with the aim of obtaining solid galenic forms, which when administered orally to patients with difficulties in swallowing, such as children, the elderly, medically uncooperative individuals with mental impairments, etc., are capable of breaking down (i.e.
fragmenting or disintegrating) rapidly, without the need for exogenous water intake, thereby facilitating the swallowing process.
Various solid galenic forms intended to break down rapidly - or relatively rapidly - in the mouth have been used. These are primarily oral lyophilisates, effervescent oral tablets, or more recently, chewable tablets or tablets with a high breakdown agents content.
Oral lyophilisates (or freeze drying tablets) represent the most commonly used rapid-breakdown compositions, in particular due to the fact that they ensure very rapid disintegration after oral administration, because of their high hygroscopicity and high
More particularly, the invention relates to a solid galenic form with rapid ingestion and facilitated swallowing.
State of the art Solid oral compositions (such as in particular medicines or food supplements/
nutritional compositions) generally come in the form of capsules or tablets.
One of the main problems posed by oral administration of solid forms such as tablets or capsules is swallowing. Indeed, approximately 35% of people in the median age group of the population suffer from dysphagia problems and struggle to swallow tablets or capsules. This percentage is significantly greater among young children and the elderly, not to mention mentally impaired or medically uncooperative persons. Such difficulties are a considerable factor in the poor compliance - or non-compliance - with treatments (in particular for long-term treatments).
In response to this problem, pharmaceutical compositions have been developed with the aim of obtaining solid galenic forms, which when administered orally to patients with difficulties in swallowing, such as children, the elderly, medically uncooperative individuals with mental impairments, etc., are capable of breaking down (i.e.
fragmenting or disintegrating) rapidly, without the need for exogenous water intake, thereby facilitating the swallowing process.
Various solid galenic forms intended to break down rapidly - or relatively rapidly - in the mouth have been used. These are primarily oral lyophilisates, effervescent oral tablets, or more recently, chewable tablets or tablets with a high breakdown agents content.
Oral lyophilisates (or freeze drying tablets) represent the most commonly used rapid-breakdown compositions, in particular due to the fact that they ensure very rapid disintegration after oral administration, because of their high hygroscopicity and high
2 porosity. Nonetheless, these lyophilisates present certain drawbacks, such as:
i) high fragility when handled, because of their high friability, ii) high sensitivity to atmospheric moisture, and iii) complex technology and manufacturing method and, consequently, high manufacturing costs. Hence, this technology is generally selected for expensive active principles with low doses in the pharmaceutical composition.
Effervescent oral tablets are made up of a pharmaceutical composition comprising an effervescent couple, which is activated upon contact with saliva, thereby ensuring complete breakdown of the tablet. However, these effervescent tablets must necessarily be of compact size in order to ensure breakdown in the mouth taking less than
i) high fragility when handled, because of their high friability, ii) high sensitivity to atmospheric moisture, and iii) complex technology and manufacturing method and, consequently, high manufacturing costs. Hence, this technology is generally selected for expensive active principles with low doses in the pharmaceutical composition.
Effervescent oral tablets are made up of a pharmaceutical composition comprising an effervescent couple, which is activated upon contact with saliva, thereby ensuring complete breakdown of the tablet. However, these effervescent tablets must necessarily be of compact size in order to ensure breakdown in the mouth taking less than
3 minutes, to limit the quantity of gas emitted and to limit the characteristic bad taste in the mouth. Another drawback of these effervescent tablets is that they are highly moisture-sensitive, which entails using a highly particular manufacturing method, typically in a controlled atmosphere.
For some years, new forms have appeared on the market, in particular in the pharmaceutical field, such as chewable (or edible) tablets, or orally disintegrating tablets. The latter have become very popular, since they present the advantage of disintegrating in the oral cavity within a few seconds, thereby avoiding the need for a swallowing effort by the patient/subject. While they have proven practical for the patient/subject, orally disintegrating tablets have generally complex compositions which, as a general rule, contain a significant number of ingredients of different kinds, including rapid-action disintegrating agents (also known as "disintegrating" agents or even "super-disintegrating" agents), which enable the tablet to break down within a few seconds in the oral cavity. Patent US 5,464,632 discloses, for example, tablets with a high disintegrating agents content. In particular, this patent discloses a pharmaceutical composition comprising in particular, as disintegrating agents associated with swelling agents, a high mass fraction of carboxymethyl cellulose and a cross-linked and insoluble polyvinylpyrrolidone (PVP). This composition is obtained by mixing an active ingredient, used in the form of microcrystals or microgranules, with a mixture of pre-granulated excipients. This high mass fraction of disintegrating agents in the compositions according to this document (and in particular of cross-linked and insoluble PVP) presents the drawback of generating a chalky type taste and an undesirable feeling of dryness, upon introducing these tablets incorporating them into the mouth.
Similarly, patent application US 2001/0009678 discloses orally disintegrating tablets, comprising:
a) a pharmaceutically active ingredient, b) one or more "sugar alcohol(s)", and c) a disintegrating agent, namely low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl" groups. Moreover, US
2001/0009678, in its "Working Example 5", sets out the preparation of an orally disintegrating tablet comprising not one, but two types of different disintegrating agents, namely the aforesaid low-substituted hydroxypropyl cellulose and crospovidone (also known as cross-linked polyvinylpyrrolidone).
Furthermore, it should be pointed out that these orally disintegrating tablets, in spite of all this, require a considerable time period (frequently of up to 30 seconds) to obtain the desired breakdown, which is not ideal if the patient/subject poses risks of "going wrong", as in cases of mentally impaired individuals (such as patients afflicted with Alzheimer's, schizophrenia, etc.). Furthermore, it should also be noted that an extended oral disintegration/breakdown time might promote oral absorption (or per-oral absorption) of the active ingredients present in this type of composition. This oral absorption phenomenon, is by its nature, prone to modify the bioavailability of the active ingredient(s) contained in the orally disintegrating tablet. Hence, an extended dwell time in the mouth can prove particularly disadvantageous in the sense that it is particularly prone to affect the bioequivalence of said orally disintegrating tablets.
Indeed, usually, the person skilled in the art develops orally disintegrating tablets with a view to making "improved" versions of traditional tablets with the objective of improving patient comfort when taking them. In terms of pharmacokinetics, these orally disintegrating tablets must remain bio-equivalent to existing traditional tablets, namely they must possess similar properties to the latter in terms of bioavailability. Yet certain active principles may exhibit absorption in the oral mucosa, which is generally proportional to the oral dwell time. If such absorption takes place due to an extended/prolonged oral dwell time, there is a risk of significantly modifying bioavailability, and of leading to non-bioequivalence of said improved composition. This is not desirable and can prove highly detrimental, since it would then be necessary to conduct costly new clinical studies with the object of measuring the impact of the change in bioavailability with regard to efficacy and safety of using the new formulation.
In pharmaco-technical terms, a major constraint concerns the limit mass of the orally disintegrating tablets and of the active principle(s) that they contain.
Indeed, these orally disintegrating tablets possess, most of the time, a mass of less than 500 mg and
For some years, new forms have appeared on the market, in particular in the pharmaceutical field, such as chewable (or edible) tablets, or orally disintegrating tablets. The latter have become very popular, since they present the advantage of disintegrating in the oral cavity within a few seconds, thereby avoiding the need for a swallowing effort by the patient/subject. While they have proven practical for the patient/subject, orally disintegrating tablets have generally complex compositions which, as a general rule, contain a significant number of ingredients of different kinds, including rapid-action disintegrating agents (also known as "disintegrating" agents or even "super-disintegrating" agents), which enable the tablet to break down within a few seconds in the oral cavity. Patent US 5,464,632 discloses, for example, tablets with a high disintegrating agents content. In particular, this patent discloses a pharmaceutical composition comprising in particular, as disintegrating agents associated with swelling agents, a high mass fraction of carboxymethyl cellulose and a cross-linked and insoluble polyvinylpyrrolidone (PVP). This composition is obtained by mixing an active ingredient, used in the form of microcrystals or microgranules, with a mixture of pre-granulated excipients. This high mass fraction of disintegrating agents in the compositions according to this document (and in particular of cross-linked and insoluble PVP) presents the drawback of generating a chalky type taste and an undesirable feeling of dryness, upon introducing these tablets incorporating them into the mouth.
Similarly, patent application US 2001/0009678 discloses orally disintegrating tablets, comprising:
a) a pharmaceutically active ingredient, b) one or more "sugar alcohol(s)", and c) a disintegrating agent, namely low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl" groups. Moreover, US
2001/0009678, in its "Working Example 5", sets out the preparation of an orally disintegrating tablet comprising not one, but two types of different disintegrating agents, namely the aforesaid low-substituted hydroxypropyl cellulose and crospovidone (also known as cross-linked polyvinylpyrrolidone).
Furthermore, it should be pointed out that these orally disintegrating tablets, in spite of all this, require a considerable time period (frequently of up to 30 seconds) to obtain the desired breakdown, which is not ideal if the patient/subject poses risks of "going wrong", as in cases of mentally impaired individuals (such as patients afflicted with Alzheimer's, schizophrenia, etc.). Furthermore, it should also be noted that an extended oral disintegration/breakdown time might promote oral absorption (or per-oral absorption) of the active ingredients present in this type of composition. This oral absorption phenomenon, is by its nature, prone to modify the bioavailability of the active ingredient(s) contained in the orally disintegrating tablet. Hence, an extended dwell time in the mouth can prove particularly disadvantageous in the sense that it is particularly prone to affect the bioequivalence of said orally disintegrating tablets.
Indeed, usually, the person skilled in the art develops orally disintegrating tablets with a view to making "improved" versions of traditional tablets with the objective of improving patient comfort when taking them. In terms of pharmacokinetics, these orally disintegrating tablets must remain bio-equivalent to existing traditional tablets, namely they must possess similar properties to the latter in terms of bioavailability. Yet certain active principles may exhibit absorption in the oral mucosa, which is generally proportional to the oral dwell time. If such absorption takes place due to an extended/prolonged oral dwell time, there is a risk of significantly modifying bioavailability, and of leading to non-bioequivalence of said improved composition. This is not desirable and can prove highly detrimental, since it would then be necessary to conduct costly new clinical studies with the object of measuring the impact of the change in bioavailability with regard to efficacy and safety of using the new formulation.
In pharmaco-technical terms, a major constraint concerns the limit mass of the orally disintegrating tablets and of the active principle(s) that they contain.
Indeed, these orally disintegrating tablets possess, most of the time, a mass of less than 500 mg and
4 contain a quantity of active ingredient(s) rarely greater than 200 mg, so as to be able to break down in the oral cavity preferably in less than 30 seconds.
In purely taste terms, it is generally disadvantageous to have an extended oral dwell time, in particular if the active ingredient(s) has (have) unpleasant taste(s). That is why orally disintegrating tablets generally contain one or more compounds making it possible to mask the unpleasant taste of the active ingredients that they contain (taste-masking agent(s)), such as insoluble or low-solubility polymers. By way of example, mention may be made of patent application WO 2006/047493 (corresponding to EP-A-1802285), which also discloses orally disintegrating tablets (acronym "ODT"), comprising particles which are each formed of a particulate core containing the pharmaceutical active principle, and coated with a so-called "taste-masking"
membrane comprising a mixture of polymers and of gelling substances in order to make it possible to mask the taste in the oral cavity.
Finally, from a preparation method viewpoint, manufacture of orally disintegrating tablets requires particular precautions, in particular in terms of adjustment of compression force. Indeed, if it proves to be too high, the oral breakdown time may be significantly extended, which is by definition contrary to the planned technical effect. In practice, in order to prevent this phenomenon, the compression force is often adjusted to minimal values, which has the consequence of greater mechanical fragility (friability) of such tablets in comparison to traditional tablets. Consequently, use of specific - and therefore costly - packaging such as "peelable" blisters sometimes proves necessary in order to prevent the tablet from crumbling when removed from its cell.
Furthermore, .. again because of the compression force adjusted to minimal values, particular attention must be paid to the stability of orally disintegrating tablets over time, in particular with regard to cohesion of the tablets (also known as tablet hardness), so as to ensure that a modification does not occur during product storage, which is prone to significantly affecting the breakdown time of said tablets in the oral cavity. Furthermore, on top of these numerous drawbacks (significant time period to obtain the desired breakdown, unpleasant sensations in the mouth due to use of specific disintegrating agents, need to add masking agents, friability, possible stability problems over time, etc.), there is the high cost of the disintegrating agents used within these orally disintegrating tablets.
.. Patent application US 2013/0052278 discloses compositions not in the form of tablets, but in the form of orally administrable powders, which rapidly dissolve in the oral cavity.
Although coming in a different galenic form to that of the orally disintegrating tablets discussed above, the compositions disclosed in US 2013/0052278 also require the presence of a disintegrating agent in their composition, so as to be able to dissolve/disintegrate in the oral cavity in a few seconds. This presents a number of drawbacks (see above), and in particular:
In purely taste terms, it is generally disadvantageous to have an extended oral dwell time, in particular if the active ingredient(s) has (have) unpleasant taste(s). That is why orally disintegrating tablets generally contain one or more compounds making it possible to mask the unpleasant taste of the active ingredients that they contain (taste-masking agent(s)), such as insoluble or low-solubility polymers. By way of example, mention may be made of patent application WO 2006/047493 (corresponding to EP-A-1802285), which also discloses orally disintegrating tablets (acronym "ODT"), comprising particles which are each formed of a particulate core containing the pharmaceutical active principle, and coated with a so-called "taste-masking"
membrane comprising a mixture of polymers and of gelling substances in order to make it possible to mask the taste in the oral cavity.
Finally, from a preparation method viewpoint, manufacture of orally disintegrating tablets requires particular precautions, in particular in terms of adjustment of compression force. Indeed, if it proves to be too high, the oral breakdown time may be significantly extended, which is by definition contrary to the planned technical effect. In practice, in order to prevent this phenomenon, the compression force is often adjusted to minimal values, which has the consequence of greater mechanical fragility (friability) of such tablets in comparison to traditional tablets. Consequently, use of specific - and therefore costly - packaging such as "peelable" blisters sometimes proves necessary in order to prevent the tablet from crumbling when removed from its cell.
Furthermore, .. again because of the compression force adjusted to minimal values, particular attention must be paid to the stability of orally disintegrating tablets over time, in particular with regard to cohesion of the tablets (also known as tablet hardness), so as to ensure that a modification does not occur during product storage, which is prone to significantly affecting the breakdown time of said tablets in the oral cavity. Furthermore, on top of these numerous drawbacks (significant time period to obtain the desired breakdown, unpleasant sensations in the mouth due to use of specific disintegrating agents, need to add masking agents, friability, possible stability problems over time, etc.), there is the high cost of the disintegrating agents used within these orally disintegrating tablets.
.. Patent application US 2013/0052278 discloses compositions not in the form of tablets, but in the form of orally administrable powders, which rapidly dissolve in the oral cavity.
Although coming in a different galenic form to that of the orally disintegrating tablets discussed above, the compositions disclosed in US 2013/0052278 also require the presence of a disintegrating agent in their composition, so as to be able to dissolve/disintegrate in the oral cavity in a few seconds. This presents a number of drawbacks (see above), and in particular:
5 - in economic terms, in view of the fact that such disintegrating agents generally prove expensive, but above all - in pharmacokinetic terms, because of the capacity of these disintegrating agents to increase the solubility of certain active ingredients in saliva and thereby cause a risk of per-oral absorption with the consequence of modifying the bioavailability of the active ingredient(s) contained in these compositions, which might prove particularly problematic given the reasons set out above.
Therefore the present invention is aimed at rectifying all or some of the abovementioned drawbacks.
Disclosure Therefore the object of the invention is a solid composition with rapid ingestion and facilitated swallowing, administrable to a human or animal individual, said composition being in the form of non-agglomerated solid particles, said composition comprising both the following types of particle:
- Pa particles, comprising at least one active ingredient, in sufficient quantity to administer the desired dose of active ingredient to said human or animal individual (and in so doing, to obtain the planned pharmacological or nutritional effect), and - Ps particles, rapidly soluble in saliva, said Ps particles being characterised by an apparent density equal to or greater than approximately 0.6 g.cm-3 (preferably equal to or greater than 0.6 g.cm-3), advantageously equal to or greater than approximately 0.7 g.cm-3 (preferably equal to or greater than 0.7 g.cm-3) and preferably between 0.7 and 1.5 g.cm-3 inclusive;
said Ps particles being present in said composition in sufficient quantity to enable rapid ingestion and facilitated swallowing of said Pa particles in said human or animal individual.
The inventor has discovered, surprisingly, that use, in the composition in the form of non-agglomerated solid particles according to the invention, of Ps particles of high apparent density (as defined above) made it possible in particular to:
a) facilitate swallowing of the Pa particles without it being necessary for these Pa
Therefore the present invention is aimed at rectifying all or some of the abovementioned drawbacks.
Disclosure Therefore the object of the invention is a solid composition with rapid ingestion and facilitated swallowing, administrable to a human or animal individual, said composition being in the form of non-agglomerated solid particles, said composition comprising both the following types of particle:
- Pa particles, comprising at least one active ingredient, in sufficient quantity to administer the desired dose of active ingredient to said human or animal individual (and in so doing, to obtain the planned pharmacological or nutritional effect), and - Ps particles, rapidly soluble in saliva, said Ps particles being characterised by an apparent density equal to or greater than approximately 0.6 g.cm-3 (preferably equal to or greater than 0.6 g.cm-3), advantageously equal to or greater than approximately 0.7 g.cm-3 (preferably equal to or greater than 0.7 g.cm-3) and preferably between 0.7 and 1.5 g.cm-3 inclusive;
said Ps particles being present in said composition in sufficient quantity to enable rapid ingestion and facilitated swallowing of said Pa particles in said human or animal individual.
The inventor has discovered, surprisingly, that use, in the composition in the form of non-agglomerated solid particles according to the invention, of Ps particles of high apparent density (as defined above) made it possible in particular to:
a) facilitate swallowing of the Pa particles without it being necessary for these Pa
6 particles to be dissolved or disintegrated in saliva, without requiring exogenous water intake, thanks to a surprising effect of practically immediate dissolution of Ps particles in the salivary fluid, inducing in particular an increase in the volume thereof (allowing rapid ingestion of the Pa particles without requiring a particular swallowing effort), and b) very significantly reduce the volume of solid matter to be ingested, in particular in order to prevent product loss or cause discomfort to the patient/subject.
The person skilled in the art, learning in particular the advantage of using Ps particles of high apparent density (as defined above), will determine, without excessive difficulty and if need be with the aid of routine tests, the aforesaid "sufficient quantity" of Ps particles to include in the composition according to the invention to enable rapid ingestion and facilitated swallowing of said Pa particles by said human or animal individual.
According to a preferred embodiment of the invention, the quantity of Ps particles included in the composition according to the invention is determined by the ratio between the mass of Pa particles and the mass of Ps particles (denoted Pa/Ps), which is preferably less than 10 (10/1), preferably less than 5 (5/1), advantageously less than or equal to 4 (4/1), preferably less than or equal to 3 (3/1), and particularly preferably less than or equal to 2.5 (2.5/1). Preferably, the aforesaid mass ratio Pa/Ps is less than or equal to 1 (1/1), preferably less than or equal to 0.75 (approximately 1/1.33) and advantageously less than or equal to 0.5 (1/2).
Quite clearly, and as is well known to the person skilled in the art, the quantity of Ps particles included in the composition according to the invention may also be expressed as a mass percentage (%m) (or weight percentage, %w) in relation to the total mass of Pa and Ps particles. This may be obtained from the mass ratio Pa/Ps (of value x), by applying the following equation:
%m Ps = x 100 Hence, according to the aforesaid preferred embodiment of the invention, the mass percentage of Ps particles within the composition according to the invention in relation to the total mass of Pa and Ps particles is greater than 9.09% (for example greater than 9.1%), preferably greater than 16.67% (for example greater than 17%), preferably equal
The person skilled in the art, learning in particular the advantage of using Ps particles of high apparent density (as defined above), will determine, without excessive difficulty and if need be with the aid of routine tests, the aforesaid "sufficient quantity" of Ps particles to include in the composition according to the invention to enable rapid ingestion and facilitated swallowing of said Pa particles by said human or animal individual.
According to a preferred embodiment of the invention, the quantity of Ps particles included in the composition according to the invention is determined by the ratio between the mass of Pa particles and the mass of Ps particles (denoted Pa/Ps), which is preferably less than 10 (10/1), preferably less than 5 (5/1), advantageously less than or equal to 4 (4/1), preferably less than or equal to 3 (3/1), and particularly preferably less than or equal to 2.5 (2.5/1). Preferably, the aforesaid mass ratio Pa/Ps is less than or equal to 1 (1/1), preferably less than or equal to 0.75 (approximately 1/1.33) and advantageously less than or equal to 0.5 (1/2).
Quite clearly, and as is well known to the person skilled in the art, the quantity of Ps particles included in the composition according to the invention may also be expressed as a mass percentage (%m) (or weight percentage, %w) in relation to the total mass of Pa and Ps particles. This may be obtained from the mass ratio Pa/Ps (of value x), by applying the following equation:
%m Ps = x 100 Hence, according to the aforesaid preferred embodiment of the invention, the mass percentage of Ps particles within the composition according to the invention in relation to the total mass of Pa and Ps particles is greater than 9.09% (for example greater than 9.1%), preferably greater than 16.67% (for example greater than 17%), preferably equal
7 to or greater than 20%, preferably equal to or greater than 25%, and particularly preferably equal to or greater than 28.57% (for example equal to or greater than 30%).
Preferably, the mass percentage of Ps particles within the composition according to the invention in relation to the total mass of Pa and Ps particles is equal to or greater than 50%, preferably equal to or greater than 57.14% and advantageously equal to or greater than 66.67% (for example equal to or greater than 70%).
According to an embodiment of the invention, the mass percentage of Ps particles within the composition according to the invention in relation to the total mass of Pa and Ps particles is less than or equal to 99%.
According to a particularly preferred embodiment of the invention, the Pa particles are particles with very low solubility in saliva. In this particularly preferred embodiment of the invention, the Pa and Ps particles are "particles with differential solubility in saliva".
According to a particularly preferred embodiment of the invention, the composition comprises a homogeneous mixture of Pa and Ps particles.
Preferably, the composition is a homogeneous mixture of non-agglomerated solid particles. This homogeneous mixture of non-agglomerated solid particles is suitable for being in packed in sachets and/or sticks, preferably in single-dose sachets and/or sticks. In other words, another object of the invention is a solid composition with rapid ingestion and facilitated swallowing, comprising a homogeneous mixture of non-agglomerated solid particles, said mixture comprising, consisting primarily of, or consisting of, the two following different types of particle:
- Pa particles, comprising at least one active ingredient, - Ps particles, rapidly soluble in saliva, said Ps particles having an apparent density equal to or greater than approximately 0.6 g.cm-3 (preferably equal to or greater than 0.6 g.cm-3), advantageously equal to or greater than approximately 0.7 g.cm-3 (preferably equal to or greater than 0.7 g.cm-3), and preferably between 0.7 and 1.5 g.cm-3 inclusive.
Advantageously, the Ps particles comprise at least one polyol with low glycaemic index, such as erythritol, preferably in a mass percentage representing at least 50%
of the total mass of the Ps particles.
According to a preferred embodiment, the Ps particles also comprise at least one
Preferably, the mass percentage of Ps particles within the composition according to the invention in relation to the total mass of Pa and Ps particles is equal to or greater than 50%, preferably equal to or greater than 57.14% and advantageously equal to or greater than 66.67% (for example equal to or greater than 70%).
According to an embodiment of the invention, the mass percentage of Ps particles within the composition according to the invention in relation to the total mass of Pa and Ps particles is less than or equal to 99%.
According to a particularly preferred embodiment of the invention, the Pa particles are particles with very low solubility in saliva. In this particularly preferred embodiment of the invention, the Pa and Ps particles are "particles with differential solubility in saliva".
According to a particularly preferred embodiment of the invention, the composition comprises a homogeneous mixture of Pa and Ps particles.
Preferably, the composition is a homogeneous mixture of non-agglomerated solid particles. This homogeneous mixture of non-agglomerated solid particles is suitable for being in packed in sachets and/or sticks, preferably in single-dose sachets and/or sticks. In other words, another object of the invention is a solid composition with rapid ingestion and facilitated swallowing, comprising a homogeneous mixture of non-agglomerated solid particles, said mixture comprising, consisting primarily of, or consisting of, the two following different types of particle:
- Pa particles, comprising at least one active ingredient, - Ps particles, rapidly soluble in saliva, said Ps particles having an apparent density equal to or greater than approximately 0.6 g.cm-3 (preferably equal to or greater than 0.6 g.cm-3), advantageously equal to or greater than approximately 0.7 g.cm-3 (preferably equal to or greater than 0.7 g.cm-3), and preferably between 0.7 and 1.5 g.cm-3 inclusive.
Advantageously, the Ps particles comprise at least one polyol with low glycaemic index, such as erythritol, preferably in a mass percentage representing at least 50%
of the total mass of the Ps particles.
According to a preferred embodiment, the Ps particles also comprise at least one
8 natural organic acid, or a salt thereof, preferably a metabolically non-acidifying natural organic acid, such as citric acid and/or a salt thereof, such as calcium citrate or magnesium citrate, Advantageously, said at least one natural organic acid, or a salt thereof, is present in the Ps particles in a mass percentage not exceeding 50% of the total mass of the Ps particles.
According to a preferred embodiment, the weight ratio of natural organic acid(s) (or a salt (salts) thereof) / polyol(s) with low glycaemic index is between 0.01 and 1 inclusive.
According to a preferred embodiment, the Ps particles have an average size of less than or equal to approximately 500 pm (preferably less than or equal to 500 pm);
preferably said Ps particles have a size range of between approximately 50 pm and approximately 500 pm (preferably between 50 pm and 500 pm), preferably between approximately 100 pm and approximately 500 pm (preferably between 100 pm and pm), advantageously between approximately 200 pm and approximately 400 pm (preferably between 200 pm and 400 pm).
According to a preferred embodiment, the Ps particles are free from disintegrating agents such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose (such as for example low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl"
groups, disclosed in US 2001/0009678).
According to a preferred embodiment, the composition according to the invention is free from disintegrating agents such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose (such as for example low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl" groups, disclosed in US 2001/0009678).
The fact that the Ps particles and/or the composition according to the invention (advantageously both) is/are free from disintegrating agents (such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose) makes it possible to rectify the drawbacks presented above. In particular, it makes it possible to reduce the cost of the product and prevent potential unfavourable impacts on per-oral absorption of the active principle(s) contained in the present
According to a preferred embodiment, the weight ratio of natural organic acid(s) (or a salt (salts) thereof) / polyol(s) with low glycaemic index is between 0.01 and 1 inclusive.
According to a preferred embodiment, the Ps particles have an average size of less than or equal to approximately 500 pm (preferably less than or equal to 500 pm);
preferably said Ps particles have a size range of between approximately 50 pm and approximately 500 pm (preferably between 50 pm and 500 pm), preferably between approximately 100 pm and approximately 500 pm (preferably between 100 pm and pm), advantageously between approximately 200 pm and approximately 400 pm (preferably between 200 pm and 400 pm).
According to a preferred embodiment, the Ps particles are free from disintegrating agents such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose (such as for example low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl"
groups, disclosed in US 2001/0009678).
According to a preferred embodiment, the composition according to the invention is free from disintegrating agents such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose (such as for example low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl" groups, disclosed in US 2001/0009678).
The fact that the Ps particles and/or the composition according to the invention (advantageously both) is/are free from disintegrating agents (such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose) makes it possible to rectify the drawbacks presented above. In particular, it makes it possible to reduce the cost of the product and prevent potential unfavourable impacts on per-oral absorption of the active principle(s) contained in the present
9 invention Indeed, unlike the compositions described for example in patent US 5,464,632 or patent application US 2001/0009678, the present invention concerns a composition wherein the particles are not agglomerated and which makes it possible to obtain rapid ingestion and facilitated swallowing of the active ingredient(s) contained within the Pa particles advantageously in the absence of disintegrating agents.
According to one embodiment, the Pa particles are made up of or are coated with a .. hydrophobic material in order to:
- protect them from moisture and/or limit their solubility in saliva, and/or - modulate the release of at least one active ingredient contained therein (such as modified release, facilitated, delayed and/or targeted release) in one or more parts of the digestive tract.
Preferably, the Pa particles have an average size of less than approximately pm (preferably less than 500 pm); preferably said Pa particles have a size range of between approximately 50 pm and approximately 500 pm (preferably between 50 pm and 500 pm), advantageously between approximately 100 pm and approximately 400 pm (preferably between 100 pm and 400 pm). Indeed, the Pa particles have a sufficiently "small" size to facilitate swallowing and prevent the patient/subject from being tempted to crunch up the particles, but sufficiently "big" to pour enable a good product flow.
According to a preferred embodiment, the average size of the Ps particles and the average size of the Pa particles are no more than 50%, and preferably no more than 25%, different from each other.
Another object of the invention is a medicine with rapid ingestion and facilitated swallowing or a food supplement with rapid ingestion and facilitated swallowing, for human or animal use, comprising the composition as defined previously.
Another object of the invention concerns a sachet or stick, preferably hermetically sealed, comprising:
- the composition according to the invention as defined above, or - the medicine with rapid ingestion and facilitated swallowing or the food supplement with rapid ingestion and facilitated swallowing as defined above.
Another object of the invention is the use of a composition as defined above for the preparation of a medicine with rapid ingestion and facilitated swallowing or a food 5 .. supplement with rapid ingestion and facilitated swallowing, for human or animal use.
Another object of the invention concerns the Ps particles as defined previously.
The inventor has discovered that this composition enabled rapid ingestion and facilitated swallowing of significant weight quantities of Pa particles, typically greater
According to one embodiment, the Pa particles are made up of or are coated with a .. hydrophobic material in order to:
- protect them from moisture and/or limit their solubility in saliva, and/or - modulate the release of at least one active ingredient contained therein (such as modified release, facilitated, delayed and/or targeted release) in one or more parts of the digestive tract.
Preferably, the Pa particles have an average size of less than approximately pm (preferably less than 500 pm); preferably said Pa particles have a size range of between approximately 50 pm and approximately 500 pm (preferably between 50 pm and 500 pm), advantageously between approximately 100 pm and approximately 400 pm (preferably between 100 pm and 400 pm). Indeed, the Pa particles have a sufficiently "small" size to facilitate swallowing and prevent the patient/subject from being tempted to crunch up the particles, but sufficiently "big" to pour enable a good product flow.
According to a preferred embodiment, the average size of the Ps particles and the average size of the Pa particles are no more than 50%, and preferably no more than 25%, different from each other.
Another object of the invention is a medicine with rapid ingestion and facilitated swallowing or a food supplement with rapid ingestion and facilitated swallowing, for human or animal use, comprising the composition as defined previously.
Another object of the invention concerns a sachet or stick, preferably hermetically sealed, comprising:
- the composition according to the invention as defined above, or - the medicine with rapid ingestion and facilitated swallowing or the food supplement with rapid ingestion and facilitated swallowing as defined above.
Another object of the invention is the use of a composition as defined above for the preparation of a medicine with rapid ingestion and facilitated swallowing or a food 5 .. supplement with rapid ingestion and facilitated swallowing, for human or animal use.
Another object of the invention concerns the Ps particles as defined previously.
The inventor has discovered that this composition enabled rapid ingestion and facilitated swallowing of significant weight quantities of Pa particles, typically greater
10 than 200 mg, advantageously greater than 500 mg and possibly up to more than one gram of Pa particles within just a few seconds, without risks of oral absorption for the patient; another characteristic of said composition is coming in a compact volume. This characteristic is also particularly important since it enables all types of patients -including those afflicted by dysphagia - to easily and rapidly ingest doses of one or more active ingredient(s) greater than 200 mg and 500 mg, potentially even exceeding one gram, without risk of modification of the bioavailability of the active ingredient(s) (a consequence of oral absorption well known to the person skilled in the art as mentioned above). Surprisingly, the inventor discovered that it was not necessary for all the particles to be dissolved in the oral cavity to obtain such properties, but only a fraction thereof (Ps particles).
The combination of Pa and Ps particles, advantageously in the form of a homogeneous mixture, making it possible to ensure rapid ingestion (typically in less than 10 seconds and advantageously in less than 5 seconds) and without a particular swallowing effort (facilitated swallowing), is also simple to prepare, which represents a certain asset.
Indeed, this mixture in particular does not need to be pre-compressed to be administered to the patient/subject. This makes it possible, among other things, to overcome the problems of friability and stability over time which are inherent in the orally disintegrating tablets from the prior art (see above). Due to the high apparent density of the Ps particles, this homogeneous mixture comes in a minimal volume, which enables the patient to easily ingest significant quantities of active ingredient, typically greater than 200 mg, very rapidly (namely without it being necessary to observe a specific breakdown time) and without requiring the use of a disintegrating agent (also known as "super-disintegrating agent"), which represents a definite saving and reduces the risk of observing a modification of bioavailability due to the phenomenon of per-oral absorption, as explained above.
=
The combination of Pa and Ps particles, advantageously in the form of a homogeneous mixture, making it possible to ensure rapid ingestion (typically in less than 10 seconds and advantageously in less than 5 seconds) and without a particular swallowing effort (facilitated swallowing), is also simple to prepare, which represents a certain asset.
Indeed, this mixture in particular does not need to be pre-compressed to be administered to the patient/subject. This makes it possible, among other things, to overcome the problems of friability and stability over time which are inherent in the orally disintegrating tablets from the prior art (see above). Due to the high apparent density of the Ps particles, this homogeneous mixture comes in a minimal volume, which enables the patient to easily ingest significant quantities of active ingredient, typically greater than 200 mg, very rapidly (namely without it being necessary to observe a specific breakdown time) and without requiring the use of a disintegrating agent (also known as "super-disintegrating agent"), which represents a definite saving and reduces the risk of observing a modification of bioavailability due to the phenomenon of per-oral absorption, as explained above.
=
11 As stated previously, the composition according to the invention comes in the form of a mixture of non-agglomerated particles, said particles not being agglomerated to each other ("free" or "non-cohesive" particles), as opposed to galenic forms comprising particles agglomerated together such as compressed solid forms.
According to an embodiment of the invention, the particles flow freely when, for example, the European Pharmacopoeia's so-called "funnel" test (see European Pharmacopoeia 8.0, "2. Analytical methods", 2.9.16) is performed, on a sample of the composition according to the invention. In the context of this "funnel" test, it is considered that the particles flow freely if, when this test is implemented, a typical flow of 100 g of sample is obtained in less than 20 seconds, preferably in less than 10 seconds.
Furthermore, said particles possess, optimally, size and apparent density characteristics which give them suitable flow properties and a low volatility so as to facilitate manufacturing of the product and reduce inhalation risks for the manufacturing preparer/operative and/or the patient/subject. That is why, according to a preferred embodiment of the invention, said composition comprises multiple non-agglomerated particles, suitable for being packed in sachets and/or sticks (preferably in single-dose sachets and/or sticks)).
Advantageously, the Ps and Pa particles do not need to be compressed together, even to form other free particles, which facilitates preparation of the composition according to the invention and prevents use of a disintegrating agent(s) within said composition.
In summary, the solid composition with rapid ingestion and facilitated swallowing according to the invention proves to be particularly advantageous, insofar as said composition:
- is easy to prepare, - makes it possible to overcome the problems of friability, breakdown time and stability over time encountered with the orally disintegrating tablets from the prior art (such as those disclosed in US 2001/0009678 and WO 2006/047493), - allows rapid ingestion and facilitated swallowing of large weight quantities of particles comprising at least one active ingredient, without it being necessary to observe a specific breakdown time for the Pa particles to be dissolved or disintegrated.
- is administrable to all types of patient (including those affected by dysphagia),
According to an embodiment of the invention, the particles flow freely when, for example, the European Pharmacopoeia's so-called "funnel" test (see European Pharmacopoeia 8.0, "2. Analytical methods", 2.9.16) is performed, on a sample of the composition according to the invention. In the context of this "funnel" test, it is considered that the particles flow freely if, when this test is implemented, a typical flow of 100 g of sample is obtained in less than 20 seconds, preferably in less than 10 seconds.
Furthermore, said particles possess, optimally, size and apparent density characteristics which give them suitable flow properties and a low volatility so as to facilitate manufacturing of the product and reduce inhalation risks for the manufacturing preparer/operative and/or the patient/subject. That is why, according to a preferred embodiment of the invention, said composition comprises multiple non-agglomerated particles, suitable for being packed in sachets and/or sticks (preferably in single-dose sachets and/or sticks)).
Advantageously, the Ps and Pa particles do not need to be compressed together, even to form other free particles, which facilitates preparation of the composition according to the invention and prevents use of a disintegrating agent(s) within said composition.
In summary, the solid composition with rapid ingestion and facilitated swallowing according to the invention proves to be particularly advantageous, insofar as said composition:
- is easy to prepare, - makes it possible to overcome the problems of friability, breakdown time and stability over time encountered with the orally disintegrating tablets from the prior art (such as those disclosed in US 2001/0009678 and WO 2006/047493), - allows rapid ingestion and facilitated swallowing of large weight quantities of particles comprising at least one active ingredient, without it being necessary to observe a specific breakdown time for the Pa particles to be dissolved or disintegrated.
- is administrable to all types of patient (including those affected by dysphagia),
12 - proves to be more economic than orally disintegrating tablets - such as those disclosed in US 2001/0009678 and WO 2006/047493 - requiring the presence of expensive disintegrating agents, - makes it possible to limit the risk of observing a modification of the bioavailability of the active ingredient because of the phenomenon of per-oral absorption, and - makes it possible to prevent an unpleasant sensation in the mouth.
Definitions Solid composition with rapid ingestion and facilitated swallowing. "Solid composition with rapid ingestion and facilitated swallowing" is taken to mean, in the sense of the present invention, a solid composition enabling:
- rapid ingestion such that the maximum oral dwell time does not exceed 10 seconds in the oral cavity and is advantageously less than 5 seconds, - facilitated/easy swallowing, said swallowing being facilitated by solubilisation of the Ps particles (see definition below) in saliva, inside the oral cavity.
Indeed, the inventor has discovered, against all expectation, that the solubilisation/dissolution of Ps particles in saliva resulted in a rapid increase in salivary volume, with the effect of enabling ingestion of the Pa particles (see definition below), without any particular swallowing effort and without it being necessary for said Pa particles to be dissolved in saliva.
Particle. The term "particle" designates a solid, discrete, small-sized element comprising one or more substances. In the context of the invention, this size is preferably less than 1 mm and greater than 0.05 mm, in particular in order to:
i) prevent excessively fine particles from being inhaled by the manufacturing preparer/operative and/or the patient/subject, and ii) facilitate product preparation while limiting air-borne contamination in the manufacturing workshops.
Reference test for determining particle solubility in saliva. Particle solubility in saliva is determined as follows: 500 mg of particles are placed in a 5 mL
volume of water for a predetermined time (for example, 10 seconds, 20 seconds or 30 seconds) under gentle stirring at 37 C. A suitable determination protocol consists for example in placing 500 mg of Ps particles or Pa particles in a test tube pre-filled with 5 mL of water at 37 C and stirring the test tube with a Vortex type stirrer for a predetermined time (for example, 10 seconds, 20 seconds or 30 seconds). In case of partial dissolution or
Definitions Solid composition with rapid ingestion and facilitated swallowing. "Solid composition with rapid ingestion and facilitated swallowing" is taken to mean, in the sense of the present invention, a solid composition enabling:
- rapid ingestion such that the maximum oral dwell time does not exceed 10 seconds in the oral cavity and is advantageously less than 5 seconds, - facilitated/easy swallowing, said swallowing being facilitated by solubilisation of the Ps particles (see definition below) in saliva, inside the oral cavity.
Indeed, the inventor has discovered, against all expectation, that the solubilisation/dissolution of Ps particles in saliva resulted in a rapid increase in salivary volume, with the effect of enabling ingestion of the Pa particles (see definition below), without any particular swallowing effort and without it being necessary for said Pa particles to be dissolved in saliva.
Particle. The term "particle" designates a solid, discrete, small-sized element comprising one or more substances. In the context of the invention, this size is preferably less than 1 mm and greater than 0.05 mm, in particular in order to:
i) prevent excessively fine particles from being inhaled by the manufacturing preparer/operative and/or the patient/subject, and ii) facilitate product preparation while limiting air-borne contamination in the manufacturing workshops.
Reference test for determining particle solubility in saliva. Particle solubility in saliva is determined as follows: 500 mg of particles are placed in a 5 mL
volume of water for a predetermined time (for example, 10 seconds, 20 seconds or 30 seconds) under gentle stirring at 37 C. A suitable determination protocol consists for example in placing 500 mg of Ps particles or Pa particles in a test tube pre-filled with 5 mL of water at 37 C and stirring the test tube with a Vortex type stirrer for a predetermined time (for example, 10 seconds, 20 seconds or 30 seconds). In case of partial dissolution or
13 absence/near-absence of dissolution (for example in the case of Pa particles), any undissolved particles are collected on a filter. Any undissolved particles are oven-dried at approximately 40 C and then weighed. Then the mass fraction of dissolved particles is determined by applying the formula below:
(initial mass of particles - weighed mass of undissolved particles) / initial mass of particles.
Quite clearly, the percentage mass is obtained by multiplying the mass fraction by 100.
Ps particles. "Ps particles" is taken to mean, in the sense of the present invention, particles rapidly soluble in saliva characterised in that, when the "reference test to determine particle solubility in saliva" described above is applied, more than 50%, preferably more than 75%, advantageously more than 90%, and preferably 100%, of the initial mass of particles is solubilised/dissolved in saliva in less than 30 seconds, preferably in less than 20 seconds, advantageously in less than 10 seconds, and particularly preferably in less than 5 seconds. Such a solubilisation/dissolution is generally known as "quasi-immediate" solubilisation or "quasi-immediate"
dissolution.
The inventor has discovered that these Ps particles, of high apparent specific gravity/density, made it possible in particular to facilitate swallowing of the Pa particles (see definition below), without it being necessary for these Pa particles to be dissolved or disintegrated in saliva. This is obtained by a surprising effect of quasi-immediate dissolution of the Ps particles in the salivary fluid, inducing in particular an increase in the volume thereof (allowing rapid ingestion of the Pa particles without needing any particular swallowing effort).
According to a particularly preferred embodiment, the aforesaid Ps particles (also known as with "quasi-immediate dissolution in saliva" or also with "quasi-immediate solubilisation in saliva") are characterised by a sufficiently high apparent density, so as to very significantly reduce the volume of solid matter to be ingested. This is a particularly important characteristic of the invention since the composition which is the object of the present invention is designed to be introduced directly into the mouth (preferably on the tongue) of the person wishing to ingest the active ingredient, and then directly swallowed by them without needing exogenous water intake (such as a glass of water). Consequently, the volume of said composition to be ingested should
(initial mass of particles - weighed mass of undissolved particles) / initial mass of particles.
Quite clearly, the percentage mass is obtained by multiplying the mass fraction by 100.
Ps particles. "Ps particles" is taken to mean, in the sense of the present invention, particles rapidly soluble in saliva characterised in that, when the "reference test to determine particle solubility in saliva" described above is applied, more than 50%, preferably more than 75%, advantageously more than 90%, and preferably 100%, of the initial mass of particles is solubilised/dissolved in saliva in less than 30 seconds, preferably in less than 20 seconds, advantageously in less than 10 seconds, and particularly preferably in less than 5 seconds. Such a solubilisation/dissolution is generally known as "quasi-immediate" solubilisation or "quasi-immediate"
dissolution.
The inventor has discovered that these Ps particles, of high apparent specific gravity/density, made it possible in particular to facilitate swallowing of the Pa particles (see definition below), without it being necessary for these Pa particles to be dissolved or disintegrated in saliva. This is obtained by a surprising effect of quasi-immediate dissolution of the Ps particles in the salivary fluid, inducing in particular an increase in the volume thereof (allowing rapid ingestion of the Pa particles without needing any particular swallowing effort).
According to a particularly preferred embodiment, the aforesaid Ps particles (also known as with "quasi-immediate dissolution in saliva" or also with "quasi-immediate solubilisation in saliva") are characterised by a sufficiently high apparent density, so as to very significantly reduce the volume of solid matter to be ingested. This is a particularly important characteristic of the invention since the composition which is the object of the present invention is designed to be introduced directly into the mouth (preferably on the tongue) of the person wishing to ingest the active ingredient, and then directly swallowed by them without needing exogenous water intake (such as a glass of water). Consequently, the volume of said composition to be ingested should
14 advantageously be as small as possible in order to facilitate swallowing.
Indeed, if the volume of particles is too great, it will be hard to introduce the whole of it onto the tongue of the patient/subject without a risk of product loss or there is a risk of causing discomfort for the patient/subject.
The high apparent density of Ps particles makes it possible to very significantly reduce the volume of dry matter to be ingested. As stated previously, Ps particles have a high apparent density, namely equal to or greater than approximately 0.6 g.cm-3, advantageously equal to or greater than approximately 0.7 g.cm-3, and preferably between 0.7 and 1.5 g.cm-3 inclusive.
According to a preferred embodiment, these Ps particles have an average size of less than or equal to 500 pm (advantageously less than 500 pm). Preferably, these Ps particles have a size range of between 100 pm and 500 pm, advantageously between 200 pm and 400 pm, in order to facilitate swallowing the product. These Ps particles (like Pa particles for that matter) preferably have an average size of greater than 50 pm in order to have sufficient pourability to facilitate the manufacture and use of the composition according to the invention and/or prevent any risk of inhalation by the manufacturing preparer and/ or the subject/patient, for example when opening the packaging (also an important characteristic to take into account). This sufficient pourability is determined/evaluated by implementing, for example, the European Pharmacopoeia's so-called "funnel" test (see European Pharmacopoeia 8.0, "2.
Analytical methods", 2.9.16). As is known to the person skilled in the art, this "funnel"
test makes it possible to qualify pourability as being "sufficient", if, when this test is implemented, a flow of 100 g of sample is obtained in less than 20 seconds, preferably in less than 10 seconds.
According to a preferred embodiment, the Ps particles do not contain a disintegrating agent such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose (such as for example low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl"
groups, disclosed in US 2001/0009678). In fact, the composition developed by the inventor makes it possible to overcome the need to use such disintegrating agents and the drawbacks associated with them (see above).
According to an embodiment of the invention, Ps particles may contain other compounds making it possible to improve the manufacture or obtain a more pleasant taste, such as sweeteners preferably of natural origin such as extracts of Stevie rebaudiana or flavourings suitable for human or veterinary use, preferably of natural origin, such as plant extracts (for example orange, lemon, grapefruit, strawberry, raspberry, cranberry, redcurrant, blueberry, blackcurrant, mint...) with a view to improving the taste perception of the composition comprising these Ps particles.
Ps particles may be prepared via conventional techniques such as granulation, extrusion, crystallisation, nebulisation, beading and may, if applicable, be coated with an external shell.
10 Particle size. In order to characterise the particle size, use is made of, for example, a granulometric analysis by means of sieving, which is a traditional method described in the European Pharmacopoeia using a column of sieves of decreasing size subjected to a mechanical vibration system, making it possible for the particles to be distributed by size on the different sieves. After weighing the quantities of particles on each sieve, the
Indeed, if the volume of particles is too great, it will be hard to introduce the whole of it onto the tongue of the patient/subject without a risk of product loss or there is a risk of causing discomfort for the patient/subject.
The high apparent density of Ps particles makes it possible to very significantly reduce the volume of dry matter to be ingested. As stated previously, Ps particles have a high apparent density, namely equal to or greater than approximately 0.6 g.cm-3, advantageously equal to or greater than approximately 0.7 g.cm-3, and preferably between 0.7 and 1.5 g.cm-3 inclusive.
According to a preferred embodiment, these Ps particles have an average size of less than or equal to 500 pm (advantageously less than 500 pm). Preferably, these Ps particles have a size range of between 100 pm and 500 pm, advantageously between 200 pm and 400 pm, in order to facilitate swallowing the product. These Ps particles (like Pa particles for that matter) preferably have an average size of greater than 50 pm in order to have sufficient pourability to facilitate the manufacture and use of the composition according to the invention and/or prevent any risk of inhalation by the manufacturing preparer and/ or the subject/patient, for example when opening the packaging (also an important characteristic to take into account). This sufficient pourability is determined/evaluated by implementing, for example, the European Pharmacopoeia's so-called "funnel" test (see European Pharmacopoeia 8.0, "2.
Analytical methods", 2.9.16). As is known to the person skilled in the art, this "funnel"
test makes it possible to qualify pourability as being "sufficient", if, when this test is implemented, a flow of 100 g of sample is obtained in less than 20 seconds, preferably in less than 10 seconds.
According to a preferred embodiment, the Ps particles do not contain a disintegrating agent such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose (such as for example low-substituted hydroxypropyl cellulose comprising 7.0 to 9.9 percent by weight "hydroxypropoxyl"
groups, disclosed in US 2001/0009678). In fact, the composition developed by the inventor makes it possible to overcome the need to use such disintegrating agents and the drawbacks associated with them (see above).
According to an embodiment of the invention, Ps particles may contain other compounds making it possible to improve the manufacture or obtain a more pleasant taste, such as sweeteners preferably of natural origin such as extracts of Stevie rebaudiana or flavourings suitable for human or veterinary use, preferably of natural origin, such as plant extracts (for example orange, lemon, grapefruit, strawberry, raspberry, cranberry, redcurrant, blueberry, blackcurrant, mint...) with a view to improving the taste perception of the composition comprising these Ps particles.
Ps particles may be prepared via conventional techniques such as granulation, extrusion, crystallisation, nebulisation, beading and may, if applicable, be coated with an external shell.
10 Particle size. In order to characterise the particle size, use is made of, for example, a granulometric analysis by means of sieving, which is a traditional method described in the European Pharmacopoeia using a column of sieves of decreasing size subjected to a mechanical vibration system, making it possible for the particles to be distributed by size on the different sieves. After weighing the quantities of particles on each sieve, the
15 results can be expressed in the form of a size histogram or it is possible to indicate the proportion of particles greater than or less than a given size (sieve mesh).
For example using this principle, it will be possible to express the percentage of particles less than 1000 pm, 710 pm, 500 pm, 355 pm, 250 pm, 180 pm 125 pm, 90 pm for the arithmetic progressions described in the Pharmacopoeia.
Polyol(s) with low glycaemic index. According to a particularly preferred aspect of the invention, the Ps particles according to the invention comprise at least one (preferably one) polyol with low glycaemic index, preferably erythritol ((2R,3S)-butane-1,2,3,4-tetraol;
CAS No.: 10030-58-7). "Polyol(s) with low glycaemic index" is taken to mean, in the sense of the present invention, a compound which, once ingested in the body, does not increase the glucose level in the blood plasma by more than 15 compared to a glucose control value (set by definition at 100). Other polyols with low glycaemic index which can be used within the composition according to the invention are for example, mannitol, lactilol, sorbitol, xylitol, iso-maltilol (or possibly maltitol).
Advantageously, the polyol with low glycaemic index, such as erythritol, is present in the Ps particles in a mass percentage representing at least 50% of the total mass of the Ps particles.
Particularly advantageously, use of the Ps particles comprising at least once polyol with low glycaemic index makes it possible to confer on the preparation taste properties, such as a pleasant taste, which enables one or more grams of product to be taken
For example using this principle, it will be possible to express the percentage of particles less than 1000 pm, 710 pm, 500 pm, 355 pm, 250 pm, 180 pm 125 pm, 90 pm for the arithmetic progressions described in the Pharmacopoeia.
Polyol(s) with low glycaemic index. According to a particularly preferred aspect of the invention, the Ps particles according to the invention comprise at least one (preferably one) polyol with low glycaemic index, preferably erythritol ((2R,3S)-butane-1,2,3,4-tetraol;
CAS No.: 10030-58-7). "Polyol(s) with low glycaemic index" is taken to mean, in the sense of the present invention, a compound which, once ingested in the body, does not increase the glucose level in the blood plasma by more than 15 compared to a glucose control value (set by definition at 100). Other polyols with low glycaemic index which can be used within the composition according to the invention are for example, mannitol, lactilol, sorbitol, xylitol, iso-maltilol (or possibly maltitol).
Advantageously, the polyol with low glycaemic index, such as erythritol, is present in the Ps particles in a mass percentage representing at least 50% of the total mass of the Ps particles.
Particularly advantageously, use of the Ps particles comprising at least once polyol with low glycaemic index makes it possible to confer on the preparation taste properties, such as a pleasant taste, which enables one or more grams of product to be taken
16 orally.
Furthermore, use of Ps particles comprising at least one polyol with low glycaemic index - and preferably erythritol - also makes it possible to obtain compositions potentially suitable for all types of subjects, in particular those who must monitor their glycaemic index for medical reasons (diabetic subjects). This represents a significant advantage.
Natural organic acid. Particularly advantageously, Ps particles comprise, are essentially composed of, or are composed of at least one polyol with low glycaemic index, as stated previously, and at least one natural organic acid, such as citric acid, or a salt thereof. "Natural organic acid" is taken to mean, in the sense of the present invention, an organic acid (carbon-based) naturally present in the animal or plant kingdom and compatible for pharmaceutical or nutritional use.
As natural organic acids, mention may in particular be made of (non-exhaustive list):
- hydrosoluble, such as citric, malic, tartric, lactic, glycolic, oxalic, salicylic, carbonic, formic, acetic, or propionic acid;
- including natural amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine;
- non-hydrosoluble belonging to the saturated fatty acids family such as butyric, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, cerotic, lignoceric acid; and - non-hydrosoluble belonging to the unsaturated fatty acids family such as oleic, linoleic, linolenic, arachidonic or eicosapentaenoic acid.
Use of this organic acid within the Ps particles according to the invention proves particularly advantageous in that it makes it possible in particular to obtain an increase in salivary volume (or even potentialise the increase in salivary volume induced by quasi-immediate dissolution of the Ps particles in saliva), which aids swallowing of the Pa particles.
Non-acidifying natural organic acid. Advantageously, the natural organic acid is selected from the so-called "non-acidifying" natural organic acids, i.e. an acid which possesses a negative value according to the PRAL index (Potential Renal Acid Load, as
Furthermore, use of Ps particles comprising at least one polyol with low glycaemic index - and preferably erythritol - also makes it possible to obtain compositions potentially suitable for all types of subjects, in particular those who must monitor their glycaemic index for medical reasons (diabetic subjects). This represents a significant advantage.
Natural organic acid. Particularly advantageously, Ps particles comprise, are essentially composed of, or are composed of at least one polyol with low glycaemic index, as stated previously, and at least one natural organic acid, such as citric acid, or a salt thereof. "Natural organic acid" is taken to mean, in the sense of the present invention, an organic acid (carbon-based) naturally present in the animal or plant kingdom and compatible for pharmaceutical or nutritional use.
As natural organic acids, mention may in particular be made of (non-exhaustive list):
- hydrosoluble, such as citric, malic, tartric, lactic, glycolic, oxalic, salicylic, carbonic, formic, acetic, or propionic acid;
- including natural amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine;
- non-hydrosoluble belonging to the saturated fatty acids family such as butyric, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, cerotic, lignoceric acid; and - non-hydrosoluble belonging to the unsaturated fatty acids family such as oleic, linoleic, linolenic, arachidonic or eicosapentaenoic acid.
Use of this organic acid within the Ps particles according to the invention proves particularly advantageous in that it makes it possible in particular to obtain an increase in salivary volume (or even potentialise the increase in salivary volume induced by quasi-immediate dissolution of the Ps particles in saliva), which aids swallowing of the Pa particles.
Non-acidifying natural organic acid. Advantageously, the natural organic acid is selected from the so-called "non-acidifying" natural organic acids, i.e. an acid which possesses a negative value according to the PRAL index (Potential Renal Acid Load, as
17 determined by the experimental work of Doctor Thomas Remer): REMER T, MANZ F, ["Potential renal acid load of foods and its influence on urine pH",. J Am Diet Assoc.
1995 Jul;95(7):791-7].
This index, which is expressed in milliequivalents (mEq), evaluates the acid (or alkaline) load generated in the body by a food or meal. This makes it possible to better adhere to the acid-base equilibrium of the patient/subject, in whom a modern diet generally tends to cause acid overloads (positive value of the PRAL index). Such acids are for example chosen from the group consisting of citric acid, and the salts thereof, such as calcium citrate or magnesium citrate.
Preferably the natural organic acid, such as citric acid, or a salt thereof, is present in the composition of the Ps particles in a proportion not exceeding 50% by mass of said Ps particles.
The weight ratio of natural organic acid (or a salt thereof) / polyol(s) with low glycaemic index is advantageously between 0.01 and 1 inclusive.
As stated previously, the Ps particles may be prepared via conventional techniques such as granulation, extrusion, crystallisation, nebulisation, beading and may, if applicable, be coated with an external shell. In particular, to prepare Ps particles comprising a polyol with low glycaemic index and a natural organic acid (or a salt thereof), it is possible to solubilise the compounds in a suitable solvent and then evaporate the solvents, for example via a nebulisation and drying technique.
Pa particles. The Pa particles comprise the active ingredient and generally an excipient. According to a particularly preferred embodiment of the invention, the Pa particles are particles with very low solubility in saliva (salivary fluid).
Indeed, insofar as, unlike certain compositions in the form of powders from the prior art (see in particular US 2013/0052278, discussed above), it is neither necessary, nor desirable, for Pa particles (containing the active ingredient(s)) to be dissolved/solubilised in saliva.
"Particles with very low solubility in saliva" is taken to mean particles which, when the "reference test for determining particle solubility in saliva" defined previously is applied, are characterised in that less than 10%, advantageously less than 5%, of the mass of the active ingredient(s) which they contain is dissolved in saliva after 10 seconds.
Advantageously, less than 10%, advantageously less than 5%, of the mass of the active substance(s) that they contain is dissolved in the salivary fluid after 30 seconds.
1995 Jul;95(7):791-7].
This index, which is expressed in milliequivalents (mEq), evaluates the acid (or alkaline) load generated in the body by a food or meal. This makes it possible to better adhere to the acid-base equilibrium of the patient/subject, in whom a modern diet generally tends to cause acid overloads (positive value of the PRAL index). Such acids are for example chosen from the group consisting of citric acid, and the salts thereof, such as calcium citrate or magnesium citrate.
Preferably the natural organic acid, such as citric acid, or a salt thereof, is present in the composition of the Ps particles in a proportion not exceeding 50% by mass of said Ps particles.
The weight ratio of natural organic acid (or a salt thereof) / polyol(s) with low glycaemic index is advantageously between 0.01 and 1 inclusive.
As stated previously, the Ps particles may be prepared via conventional techniques such as granulation, extrusion, crystallisation, nebulisation, beading and may, if applicable, be coated with an external shell. In particular, to prepare Ps particles comprising a polyol with low glycaemic index and a natural organic acid (or a salt thereof), it is possible to solubilise the compounds in a suitable solvent and then evaporate the solvents, for example via a nebulisation and drying technique.
Pa particles. The Pa particles comprise the active ingredient and generally an excipient. According to a particularly preferred embodiment of the invention, the Pa particles are particles with very low solubility in saliva (salivary fluid).
Indeed, insofar as, unlike certain compositions in the form of powders from the prior art (see in particular US 2013/0052278, discussed above), it is neither necessary, nor desirable, for Pa particles (containing the active ingredient(s)) to be dissolved/solubilised in saliva.
"Particles with very low solubility in saliva" is taken to mean particles which, when the "reference test for determining particle solubility in saliva" defined previously is applied, are characterised in that less than 10%, advantageously less than 5%, of the mass of the active ingredient(s) which they contain is dissolved in saliva after 10 seconds.
Advantageously, less than 10%, advantageously less than 5%, of the mass of the active substance(s) that they contain is dissolved in the salivary fluid after 30 seconds.
18 According to a preferred embodiment, Pa particles make it possible to confer on the active ingredient(s) that they contain particular properties, for example:
i) when preparing the product or storing the product, such as properties in terms of moisture protection, and ii) after ingestion of the product, such as modified release properties (for example facilitated, delayed or targeted release in one or various parts of the digestive tract).
Such particles are known as "functional Pa particles", such that one of the objects of the present invention is to enable rapid ingestion and facilitated swallowing of functional Pa particles.
In order to promote homogeneity of the mixture, the average size of the Pa particles is generally chosen from a range of 50 pm to 500 pm, advantageously from 100 pm to 400 pm. According to a particular embodiment, the chosen range is 150 pm to 300 pm, in order to facilitate swallowing of the product and advantageously slightly less than the average size of the Ps particles, in order to limit the risks of abrasion during distribution operations of the product.
Pa particles may be prepared via conventional techniques such as granulation, extrusion, crystallisation, nebulisation, beading and may, if applicable, be coated with an external shell. This may be for example a) a lipophilic compound preferably of plant origin, such as a natural fatty acid such as stearic acid, palmitic acid, oleic acid or an ester thereof based on glycerol, sorbitol, or macrogols or b) a protein or a polymer for food or pharmaceutical use such as b.1) a protein or polymer which is natural or modified for example based on cellulose, starch, alginate, xanthan, carrageenan or b.2) a synthetic polymer for example derived from acrylic, methacrylic, vinylic, lactic, glycolic acid or amino acids, or obtained by condensation of ethylene oxide, or propylene oxide, and/or various combinations thereof.
Ratio between Pa and Ps particles. The ratio between the quantity of particles Pa and Ps depends on factors such as in particular the final volume of the composition according to the invention, on the dose of active ingredient to be administered and on the dissolution sensation that is being sought. As stated above, the ratio between the mass of Pa particles and that of Ps particles according to the invention is preferably less than 10 (10/1), preferably less than 5 (5/1), advantageously less than or equal to 4 (4/1), preferably less than or equal to 3 (3/1), and particularly preferably less than or equal to 2.5 (2.5/1). Preferably, said mass ratio Pa/Ps is less than or equal to 1 (1/1), preferably less than or equal to 0.75 (approximately 1/1.33) and advantageously less
i) when preparing the product or storing the product, such as properties in terms of moisture protection, and ii) after ingestion of the product, such as modified release properties (for example facilitated, delayed or targeted release in one or various parts of the digestive tract).
Such particles are known as "functional Pa particles", such that one of the objects of the present invention is to enable rapid ingestion and facilitated swallowing of functional Pa particles.
In order to promote homogeneity of the mixture, the average size of the Pa particles is generally chosen from a range of 50 pm to 500 pm, advantageously from 100 pm to 400 pm. According to a particular embodiment, the chosen range is 150 pm to 300 pm, in order to facilitate swallowing of the product and advantageously slightly less than the average size of the Ps particles, in order to limit the risks of abrasion during distribution operations of the product.
Pa particles may be prepared via conventional techniques such as granulation, extrusion, crystallisation, nebulisation, beading and may, if applicable, be coated with an external shell. This may be for example a) a lipophilic compound preferably of plant origin, such as a natural fatty acid such as stearic acid, palmitic acid, oleic acid or an ester thereof based on glycerol, sorbitol, or macrogols or b) a protein or a polymer for food or pharmaceutical use such as b.1) a protein or polymer which is natural or modified for example based on cellulose, starch, alginate, xanthan, carrageenan or b.2) a synthetic polymer for example derived from acrylic, methacrylic, vinylic, lactic, glycolic acid or amino acids, or obtained by condensation of ethylene oxide, or propylene oxide, and/or various combinations thereof.
Ratio between Pa and Ps particles. The ratio between the quantity of particles Pa and Ps depends on factors such as in particular the final volume of the composition according to the invention, on the dose of active ingredient to be administered and on the dissolution sensation that is being sought. As stated above, the ratio between the mass of Pa particles and that of Ps particles according to the invention is preferably less than 10 (10/1), preferably less than 5 (5/1), advantageously less than or equal to 4 (4/1), preferably less than or equal to 3 (3/1), and particularly preferably less than or equal to 2.5 (2.5/1). Preferably, said mass ratio Pa/Ps is less than or equal to 1 (1/1), preferably less than or equal to 0.75 (approximately 1/1.33) and advantageously less
19 than or equal to 0.5 (1/2).
It is advantageous to choose Ps particles and Pa particles of close or similar granulometries, in order to facilitate the homogeneity of the mixture of Pa and Ps particles. Hence it is for example advantageous, in the sense of the present invention, to use Ps and Pa particles with average sizes not differing by more than 50%
and advantageously by no more than 25% from each other. Indeed, it proves particularly advantageous for the Ps and Pa particles to come in relatively close sizes so as to ensure the homogeneity of the final mixture.
Homogeneous. The qualifying adjective "homogeneous" is used, within the present patent application, in order to characterise the mixture of particles according to the invention by defining a sufficiently uniform distribution of the mixture particles. Hence, according to a preferred embodiment, the mixture of particles according to the invention is considered "homogeneous" if, within various sampling operations (generally 3 to 6 samples) performed during preparation of the product in various parts of the mixer in said mixture (for example 3 samples of at least 1 g each in the mixer in the vertical axis [top centre, middle centre and bottom centre]), the active ingredient is in proportions adhering to the theoretical formula of the final mixture with tolerated variations (variation coefficients) of up to 10% and advantageously tolerated variations of up to 5 %. Note that by way of example, the active ingredient is dosed in each sampling operation by a liquid phase chromatography technique, well known to the person skilled in the art.
Active ingredient. "Active ingredient" is taken to mean, in the sense of the present invention, any molecule or any assembly of molecules capable of making modifications or modulations to the operation of a biological system. Depending on the envisaged use, this active ingredient may be:
- a pharmaceutical active ingredient (also known as "pharmaceutical active principle";
suitable for forming part of the composition of a medicine), namely, which is designed to be ingested orally, - an active ingredient for cosmetic purposes (also known as "cosmetic active principle"), namely a non-medicinal active ingredient designed for body care and beauty (for example a molecule or set of molecules used for slimming, preventing or slowing cutaneous ageing or even improving the appearance of the skin), - a nutritional ingredient, namely at least one nutrient or a substance with nutritional or physiological effect; this nutritional ingredient is suitable for preparing a food supplement / a nutritional composition, or also - a veterinary active ingredient.
By way of illustration (though non-limiting), it is possible to envisage, as active ingredient(s), the active principles used in the pharmacological classes such as 5 Allergy, Anaesthesia, Sedation, Treatment of pain and inflammation, Cancerology haematology, Cardiology Angiology, Contraception and pregnancy interruption, Dermatology, Endocrinology, Gastro-Entero-Hepatology, Gynaecology, Haemostasis, Immunology, Infectiology, Parasitology, Metabolism, Nutrition, Neurology-psychiatry, Ophthalmology, Otorhinolaryngology, Pneumology, Diagnostic products or other 10 treatment products, Rheumatology, Blood and derivatives, Stomatology, Toxicology, Urology, Nephrology, etc.
More precisely, and again for illustrative purposes, it is possible to envisage, as active ingredient(s), the active principles used in the following pharmacological classes:
- Molecules used as anti-allergens: alimemazine, cetirizine, desloratadine, diphenhydramine doxylamine, fexofenadine, hydroxyzine, loratadine, mepyramine, promethazine, terfenadine;
- Molecules with analgesic, antalgic, sedative and anti-inflammatory properties:
acepromazine, alprazolam, amitriptyline, barbital, bromazepam, chlorpromazine, codeine, dextrometorphan, fentanyl, haloperidol, imipramine, lorazepam, midazolam, morphine, naloxone, oxomemazine, phenobarbital, sulpiride, tetrazepam, zolpidem, zopiclone, alfentanyl, buprenorphine, codethyline, dextropropoxyphene, morphine, pavot, pentazocine, sufentanil, tapentadol, tramadol, acetylsalicylic acid, betamethasone, cortisone, dexamethasone, diclofenac, hydrocortisone, ibuprofen, ketoprofen, naproxen, piroxicam, paracetamol, prednisolone, tiaprofenic acid, triamcinolone codeine, morphine, tramadol;
- Antineoplastic molecules: carboplatin, cisplatin, docetaxel, doxorubicin, etoposide, irinotecan, methotrexate, piaclitaxel, thiotepa, vincristine;
- Molecules used for cardiovascular system disorders: alprenolol, captopril, clopidogrel, digoxin, enalapril, felodipine, furosemide, heptaminol, nadolol, olmesartan, propanolol, ramipril, telmisartan, trinitrine, valsartan, verapamil;
- Sex hormones and modulators: desogestrel, levonorgestrel, progesterone, estradiol, ethinylestradiol, danazol;
- Molecules used in dermatology or dermocosmetics: acitretin, isotretinoin, retinoic acid and derivatives, omega-3-type polyunsaturated fatty acids;
- Molecules used in endocrinology: carbimazole, levothyroxine, thiamazole;
- Molecules used in gastro-entero-hepatology: aluminium carbonate, calcium carbonate, loperamide, racecadrotil, domperidone, ondansetron, cimetidine, esomeprazole, omeprazole, pantoprazole, hyoscine, mebeverine, lactulose, bisacodyl, senna, enoxolone, troxipide, cisapride, metoclopramide, alverine;
- Molecules used for modulating immune response: azathioprine, cyclosporine, mycophenolic acid and salts, sirolimus, tacrolimus;
- Molecules used in infectiology and parasitology: aciclovir, atazanavir, efavirenz, ganciclovir, indinavir, lamivudine, maraviroc, saquinavir, zidovudine, chloroquine, mefloquine, quinine, albendazole, fenbendazole, nnetronidazole, ivermectin, levamisole, niclosamide, praziquantel, amikacin, neomycin, ethambutol, rifamycin, cephalexin, ceftiofur, imipenem, chloramphenicol, vancomycin, clindamycin, azithromycin, erythromycin, amoxicillin, oxacillin, levofloxacin, orfloxacin, sulfanilamide, sulfathiazole, tetracycline, fosfomycin, amphotericin B, fluconazole, itraconazole, ketoconazole, miconazole;
- Molecules used in metabolic disorders and nutrition: acarbose, metformin, sitagliptin, glibenclamide, glicazide, tolbutamide, allopurinol, colchicine, probenecid, alendronic acid and derivatives, hydrosoluble vitamins such as group, B vitamins, vitamin C, liposoluble vitamins (A,D,E,K), minerals (such as Calcium, Magnesium, Zinc in the form of various salts);
- Molecules used in neurology and psychiatry: amantadine, bromocriptine, entacapone, levodopa, selegiline, sumatriptan, almotriptan, naratriptan, carbamazepine, clonazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, phenytoin, topiramate, valproate, amitriptyline escitalopram, fluoxetine, imipramine, mirtazapine, phenelzine, trazodone, venlafaxine;
- Molecules used for respiratory disorders: aminophylline, caffeine, formoterol, montelukast, theophylline, acetylcysteine, carbocysteine, dextromethorphan, xylometazoline;
- Molecules used as antidotes, antagonists or chelating agents: activated charcoal, dimercaprol, naloxone, penicillamine, edetic acid and derived salts;
- Molecules used in urology: finasteride, oxybutynin, papaverine, sildenafil, tadalafil, tamsulosin.
- Plant extracts used in various indications such as extracts of Curcuma longa, Boswellia serrata, Tagetes erecta, Zin giber officinale, Whitania somnifera, Allium sativum, Aloe vera, 11licum anisum, Borrago officinalis, Matricaria chamomilla, Sylbum marianum, Coriandrum sativum, Digitalis purpurea, Eucalyptus globulus, Ficus carica, Gingko biloba, Althaea officinalis, Plantago ovata, Hypericum perforatum, Myrtus communis, Vaccinium macrocarpon, Capsicum annuum, Vitis vinifera, Glycyrrhiza glabra, Salix alba, Spirulina, maxima, Valeriana officinalis.
It is also possible to envisage, as active ingredient(s), micro-organisms such as probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus plantarum, Saccharomyces boulardii, Saccharomyces cerevisiae, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium breve...).
Apparent density (or "bulk density"). As is well known to the person skilled in the art, the apparent density of a powder is taken to be the density of said powder not subjected to a compaction force and comprises the volume of the particles, the inter-particle volume and the volume of the particle pores. For more clarification in this respect, the person skilled in the art may refer, if applicable, to the definition of "bulk density" given in the European Pharmacopoeia (see European Pharmacopoeia 8.0, "2.
Analytical methods", 2.9.34, page 367). Preferably, the apparent density is determined by implementing the so-called "graduated test tube" reference method, designated as "method 1" in point 2.9.34 of European Pharmacopoeia 8.0 (page 367). Said "graduated test tube" method consists in determining the apparent density by measuring the volume occupied by a known mass of powder poured into a graduated cylinder (such as a graduated test tube of sufficient precision) after passing through a sieve (with mesh opening of at least 1.0 mm) and according to the following procedure: 100 grams of powder to be examined is introduced in a dry graduated test tube of sufficient pressure, without compacting. The reading of the volume occupied by the powder on the test tube graduation represents the apparent density normally estimated to the nearest 2 mL. For more clarification, the person skilled in the art may refer, if applicable, to point 2.9.34 of European Pharmacopoeia 8.0 (page 367), entitled "METHOD 1: GRADUATED TEST
TUBE". Methods other than the so-called "graduated test tube" may be used to determine the apparent density of the composition in the form of non-agglomerated solid particles according to the invention, such as the so-called "weighing bottle"
method - designated as "method 3" in point 2.9.34 of European Pharmacopoeia 8.0 (pages 367 and 368) - or also the so-called "volumeter" method (designated as "method 2" in point 2.9.34 of European Pharmacopoeia 8.0 (page 367); with the European Pharmacopoeia favouring said methods 1 and 3.
Detailed description The examples presented below make it possible to better illustrate the present invention. However, these examples must under no circumstances be regarded as limiting the scope of said invention in any way.
Examples Example 1: preparation of one kilogram (1 kg) of food supplement based on Zinqiber officinale composed of a homogeneous mixture of Pa and Ps particles.
10% by weight Pa particles and 90% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of white to white-cream coloured particles.
Pa particles: The Pa particles are made up of a mixture of 40% extract of Zingiber officinale (ginger) root and 60% sorbitol monostearate, and prepared according to a beading technique (technique of nebulisation followed by cooling) well known to the person skilled in the art, in order to limit their solubility in the oral cavity. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity):
indeed, a quantity less than 5% of the mass of the active ingredient, gingerol, is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva" defined above is applied, so as not to cause in particular an excessively spicy sensation in the patient's mouth. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture of 99% erythritol and 1% citric acid, and are obtained by mixing in solution and then drying. The particles present an apparent density of between 0.7 and 0.8 g.cm-3 inclusive, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm in size. The homogeneity of the mixture thus formed is assessed by taking 3 samples of at least 1 g from the mixer in the vertical axis (top centre, middle centre, bottom centre) and assaying one of the active ingredients (gingerol) via a conventional liquid chromatography technique. The results obtained are set out in table 1 below and show a variation coefficient of less than 5 `Yo.
Sample Dosage (mg) Top 188 Middle 174 Bottom 178 Mean 180 Standard 7.21 deviation VC 4.01%
Table 1 This variation coefficient, of less than 5%, confirms that the mixture of Pa and Ps particles is homogeneous, as stated previously.
The mixture thus obtained is particularly homogeneous and dense due to the high apparent density and/or the specific granulometry of the Ps particles (of between 0.1 and 1 millimetre). Furthermore, since the average particle size is more than 50 pm, it facilitates the preparation operations by limiting particle dissemination during the manufacturing operations, as well as the risk of inhalation of the product by the user when opening and taking the product.
In addition, said mixture possesses sufficient pourability (measured via the European Pharmacopoeia's so-called "funnel" test (see European Pharmacopoeia 8.0, "2.
Analytical methods", 2.9.16) which enables it to be packed and taken directly into the user's mouth (oral administration) without requiring exogenous water intake or a prior step of dilution in a glass of water.
The homogeneous mixture of Pa and Ps particles proves particularly stable in particular because of its preparation method, which makes it possible to separately prepare the Pa particles, on the one hand, and Ps particles on the other.
Example 2: preparation of one kilogram (1 kg) of food supplement based on Vaccinum macrocarpon composed of a homogeneous mixture of Pa and Ps particles.
40% by weight Pa particles and 60% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 40% extract of Vaccinium macrocarpon (cranberry) and 60% glycerol monostearate, and prepared according to a 5 beading technique (technique of nebulisation followed by cooling) well known to the person skilled in the art, in order to limit their solubility in the oral cavity. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity):
indeed, a quantity less than 5% of the mass of the active ingredient (proanthocyanidins or PACs) is dissolved after 10 seconds when the "reference test for determining particle solubility 10 in saliva" defined above is applied, so as not to cause in particular excessive acidity in the patient's mouth. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
15 Ps particles: The Ps particles are made up of a mixture of 98.5% erythritol and 1.5%
citric acid, and are obtained by granulation and then drying. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied. Granulometric analysis of the Ps particles according to the sieving
It is advantageous to choose Ps particles and Pa particles of close or similar granulometries, in order to facilitate the homogeneity of the mixture of Pa and Ps particles. Hence it is for example advantageous, in the sense of the present invention, to use Ps and Pa particles with average sizes not differing by more than 50%
and advantageously by no more than 25% from each other. Indeed, it proves particularly advantageous for the Ps and Pa particles to come in relatively close sizes so as to ensure the homogeneity of the final mixture.
Homogeneous. The qualifying adjective "homogeneous" is used, within the present patent application, in order to characterise the mixture of particles according to the invention by defining a sufficiently uniform distribution of the mixture particles. Hence, according to a preferred embodiment, the mixture of particles according to the invention is considered "homogeneous" if, within various sampling operations (generally 3 to 6 samples) performed during preparation of the product in various parts of the mixer in said mixture (for example 3 samples of at least 1 g each in the mixer in the vertical axis [top centre, middle centre and bottom centre]), the active ingredient is in proportions adhering to the theoretical formula of the final mixture with tolerated variations (variation coefficients) of up to 10% and advantageously tolerated variations of up to 5 %. Note that by way of example, the active ingredient is dosed in each sampling operation by a liquid phase chromatography technique, well known to the person skilled in the art.
Active ingredient. "Active ingredient" is taken to mean, in the sense of the present invention, any molecule or any assembly of molecules capable of making modifications or modulations to the operation of a biological system. Depending on the envisaged use, this active ingredient may be:
- a pharmaceutical active ingredient (also known as "pharmaceutical active principle";
suitable for forming part of the composition of a medicine), namely, which is designed to be ingested orally, - an active ingredient for cosmetic purposes (also known as "cosmetic active principle"), namely a non-medicinal active ingredient designed for body care and beauty (for example a molecule or set of molecules used for slimming, preventing or slowing cutaneous ageing or even improving the appearance of the skin), - a nutritional ingredient, namely at least one nutrient or a substance with nutritional or physiological effect; this nutritional ingredient is suitable for preparing a food supplement / a nutritional composition, or also - a veterinary active ingredient.
By way of illustration (though non-limiting), it is possible to envisage, as active ingredient(s), the active principles used in the pharmacological classes such as 5 Allergy, Anaesthesia, Sedation, Treatment of pain and inflammation, Cancerology haematology, Cardiology Angiology, Contraception and pregnancy interruption, Dermatology, Endocrinology, Gastro-Entero-Hepatology, Gynaecology, Haemostasis, Immunology, Infectiology, Parasitology, Metabolism, Nutrition, Neurology-psychiatry, Ophthalmology, Otorhinolaryngology, Pneumology, Diagnostic products or other 10 treatment products, Rheumatology, Blood and derivatives, Stomatology, Toxicology, Urology, Nephrology, etc.
More precisely, and again for illustrative purposes, it is possible to envisage, as active ingredient(s), the active principles used in the following pharmacological classes:
- Molecules used as anti-allergens: alimemazine, cetirizine, desloratadine, diphenhydramine doxylamine, fexofenadine, hydroxyzine, loratadine, mepyramine, promethazine, terfenadine;
- Molecules with analgesic, antalgic, sedative and anti-inflammatory properties:
acepromazine, alprazolam, amitriptyline, barbital, bromazepam, chlorpromazine, codeine, dextrometorphan, fentanyl, haloperidol, imipramine, lorazepam, midazolam, morphine, naloxone, oxomemazine, phenobarbital, sulpiride, tetrazepam, zolpidem, zopiclone, alfentanyl, buprenorphine, codethyline, dextropropoxyphene, morphine, pavot, pentazocine, sufentanil, tapentadol, tramadol, acetylsalicylic acid, betamethasone, cortisone, dexamethasone, diclofenac, hydrocortisone, ibuprofen, ketoprofen, naproxen, piroxicam, paracetamol, prednisolone, tiaprofenic acid, triamcinolone codeine, morphine, tramadol;
- Antineoplastic molecules: carboplatin, cisplatin, docetaxel, doxorubicin, etoposide, irinotecan, methotrexate, piaclitaxel, thiotepa, vincristine;
- Molecules used for cardiovascular system disorders: alprenolol, captopril, clopidogrel, digoxin, enalapril, felodipine, furosemide, heptaminol, nadolol, olmesartan, propanolol, ramipril, telmisartan, trinitrine, valsartan, verapamil;
- Sex hormones and modulators: desogestrel, levonorgestrel, progesterone, estradiol, ethinylestradiol, danazol;
- Molecules used in dermatology or dermocosmetics: acitretin, isotretinoin, retinoic acid and derivatives, omega-3-type polyunsaturated fatty acids;
- Molecules used in endocrinology: carbimazole, levothyroxine, thiamazole;
- Molecules used in gastro-entero-hepatology: aluminium carbonate, calcium carbonate, loperamide, racecadrotil, domperidone, ondansetron, cimetidine, esomeprazole, omeprazole, pantoprazole, hyoscine, mebeverine, lactulose, bisacodyl, senna, enoxolone, troxipide, cisapride, metoclopramide, alverine;
- Molecules used for modulating immune response: azathioprine, cyclosporine, mycophenolic acid and salts, sirolimus, tacrolimus;
- Molecules used in infectiology and parasitology: aciclovir, atazanavir, efavirenz, ganciclovir, indinavir, lamivudine, maraviroc, saquinavir, zidovudine, chloroquine, mefloquine, quinine, albendazole, fenbendazole, nnetronidazole, ivermectin, levamisole, niclosamide, praziquantel, amikacin, neomycin, ethambutol, rifamycin, cephalexin, ceftiofur, imipenem, chloramphenicol, vancomycin, clindamycin, azithromycin, erythromycin, amoxicillin, oxacillin, levofloxacin, orfloxacin, sulfanilamide, sulfathiazole, tetracycline, fosfomycin, amphotericin B, fluconazole, itraconazole, ketoconazole, miconazole;
- Molecules used in metabolic disorders and nutrition: acarbose, metformin, sitagliptin, glibenclamide, glicazide, tolbutamide, allopurinol, colchicine, probenecid, alendronic acid and derivatives, hydrosoluble vitamins such as group, B vitamins, vitamin C, liposoluble vitamins (A,D,E,K), minerals (such as Calcium, Magnesium, Zinc in the form of various salts);
- Molecules used in neurology and psychiatry: amantadine, bromocriptine, entacapone, levodopa, selegiline, sumatriptan, almotriptan, naratriptan, carbamazepine, clonazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, phenytoin, topiramate, valproate, amitriptyline escitalopram, fluoxetine, imipramine, mirtazapine, phenelzine, trazodone, venlafaxine;
- Molecules used for respiratory disorders: aminophylline, caffeine, formoterol, montelukast, theophylline, acetylcysteine, carbocysteine, dextromethorphan, xylometazoline;
- Molecules used as antidotes, antagonists or chelating agents: activated charcoal, dimercaprol, naloxone, penicillamine, edetic acid and derived salts;
- Molecules used in urology: finasteride, oxybutynin, papaverine, sildenafil, tadalafil, tamsulosin.
- Plant extracts used in various indications such as extracts of Curcuma longa, Boswellia serrata, Tagetes erecta, Zin giber officinale, Whitania somnifera, Allium sativum, Aloe vera, 11licum anisum, Borrago officinalis, Matricaria chamomilla, Sylbum marianum, Coriandrum sativum, Digitalis purpurea, Eucalyptus globulus, Ficus carica, Gingko biloba, Althaea officinalis, Plantago ovata, Hypericum perforatum, Myrtus communis, Vaccinium macrocarpon, Capsicum annuum, Vitis vinifera, Glycyrrhiza glabra, Salix alba, Spirulina, maxima, Valeriana officinalis.
It is also possible to envisage, as active ingredient(s), micro-organisms such as probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus plantarum, Saccharomyces boulardii, Saccharomyces cerevisiae, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium breve...).
Apparent density (or "bulk density"). As is well known to the person skilled in the art, the apparent density of a powder is taken to be the density of said powder not subjected to a compaction force and comprises the volume of the particles, the inter-particle volume and the volume of the particle pores. For more clarification in this respect, the person skilled in the art may refer, if applicable, to the definition of "bulk density" given in the European Pharmacopoeia (see European Pharmacopoeia 8.0, "2.
Analytical methods", 2.9.34, page 367). Preferably, the apparent density is determined by implementing the so-called "graduated test tube" reference method, designated as "method 1" in point 2.9.34 of European Pharmacopoeia 8.0 (page 367). Said "graduated test tube" method consists in determining the apparent density by measuring the volume occupied by a known mass of powder poured into a graduated cylinder (such as a graduated test tube of sufficient precision) after passing through a sieve (with mesh opening of at least 1.0 mm) and according to the following procedure: 100 grams of powder to be examined is introduced in a dry graduated test tube of sufficient pressure, without compacting. The reading of the volume occupied by the powder on the test tube graduation represents the apparent density normally estimated to the nearest 2 mL. For more clarification, the person skilled in the art may refer, if applicable, to point 2.9.34 of European Pharmacopoeia 8.0 (page 367), entitled "METHOD 1: GRADUATED TEST
TUBE". Methods other than the so-called "graduated test tube" may be used to determine the apparent density of the composition in the form of non-agglomerated solid particles according to the invention, such as the so-called "weighing bottle"
method - designated as "method 3" in point 2.9.34 of European Pharmacopoeia 8.0 (pages 367 and 368) - or also the so-called "volumeter" method (designated as "method 2" in point 2.9.34 of European Pharmacopoeia 8.0 (page 367); with the European Pharmacopoeia favouring said methods 1 and 3.
Detailed description The examples presented below make it possible to better illustrate the present invention. However, these examples must under no circumstances be regarded as limiting the scope of said invention in any way.
Examples Example 1: preparation of one kilogram (1 kg) of food supplement based on Zinqiber officinale composed of a homogeneous mixture of Pa and Ps particles.
10% by weight Pa particles and 90% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of white to white-cream coloured particles.
Pa particles: The Pa particles are made up of a mixture of 40% extract of Zingiber officinale (ginger) root and 60% sorbitol monostearate, and prepared according to a beading technique (technique of nebulisation followed by cooling) well known to the person skilled in the art, in order to limit their solubility in the oral cavity. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity):
indeed, a quantity less than 5% of the mass of the active ingredient, gingerol, is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva" defined above is applied, so as not to cause in particular an excessively spicy sensation in the patient's mouth. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture of 99% erythritol and 1% citric acid, and are obtained by mixing in solution and then drying. The particles present an apparent density of between 0.7 and 0.8 g.cm-3 inclusive, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm in size. The homogeneity of the mixture thus formed is assessed by taking 3 samples of at least 1 g from the mixer in the vertical axis (top centre, middle centre, bottom centre) and assaying one of the active ingredients (gingerol) via a conventional liquid chromatography technique. The results obtained are set out in table 1 below and show a variation coefficient of less than 5 `Yo.
Sample Dosage (mg) Top 188 Middle 174 Bottom 178 Mean 180 Standard 7.21 deviation VC 4.01%
Table 1 This variation coefficient, of less than 5%, confirms that the mixture of Pa and Ps particles is homogeneous, as stated previously.
The mixture thus obtained is particularly homogeneous and dense due to the high apparent density and/or the specific granulometry of the Ps particles (of between 0.1 and 1 millimetre). Furthermore, since the average particle size is more than 50 pm, it facilitates the preparation operations by limiting particle dissemination during the manufacturing operations, as well as the risk of inhalation of the product by the user when opening and taking the product.
In addition, said mixture possesses sufficient pourability (measured via the European Pharmacopoeia's so-called "funnel" test (see European Pharmacopoeia 8.0, "2.
Analytical methods", 2.9.16) which enables it to be packed and taken directly into the user's mouth (oral administration) without requiring exogenous water intake or a prior step of dilution in a glass of water.
The homogeneous mixture of Pa and Ps particles proves particularly stable in particular because of its preparation method, which makes it possible to separately prepare the Pa particles, on the one hand, and Ps particles on the other.
Example 2: preparation of one kilogram (1 kg) of food supplement based on Vaccinum macrocarpon composed of a homogeneous mixture of Pa and Ps particles.
40% by weight Pa particles and 60% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 40% extract of Vaccinium macrocarpon (cranberry) and 60% glycerol monostearate, and prepared according to a 5 beading technique (technique of nebulisation followed by cooling) well known to the person skilled in the art, in order to limit their solubility in the oral cavity. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity):
indeed, a quantity less than 5% of the mass of the active ingredient (proanthocyanidins or PACs) is dissolved after 10 seconds when the "reference test for determining particle solubility 10 in saliva" defined above is applied, so as not to cause in particular excessive acidity in the patient's mouth. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
15 Ps particles: The Ps particles are made up of a mixture of 98.5% erythritol and 1.5%
citric acid, and are obtained by granulation and then drying. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied. Granulometric analysis of the Ps particles according to the sieving
20 method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 3: preparation of one kilogram (1 kg) of food supplement based on Tagetes erecta composed of a homo_geneous mixture of Pa and Ps particles.
20% by weight Pa particles and 80% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 40% Tagetes erecta extract (lutein), 40% microcrystalline cellulose and 20% hypromellose (hydroxypropyl methylcellulose), and prepared according to a granulation technique followed by film-coating on a fluid air bed well known to the person skilled in the art, in order to improve their stability. The Pa particles also present low solubility in saliva (in the oral cavity) according to the "reference test for determining particle solubility in saliva" defined above, so as not to cause an excessively pronounced taste in the patient's mouth.
Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% in size are less than 125 pm.
Ps particles: The Ps particles are made up of a mixture composed of 60%
sorbitol, 20%
erythritol, 18% tricalcium citrate and 2% citric acid, and are obtained by granulation and drying. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied.
Granulometric analysis of the Ps particles according to the sieving method shows that more than 90%
of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 4: preparation of one kilooram_(1 kg) of food supplement based on Chlorella and Carbo vegetalis composed of a homogeneous mixture of Pa and Ps particles.
70% by weight of a mixture of Pa particles and 30% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Mixture of Pa particles: this mixture comprises equal parts of:
- Pal particles, made up of 40% Chlorella and 60% sorbitol monostearate, and - Pa2 particles, made up of 40% Garbo vegetalis (vegetable carbon) and 60%
sorbitol monostearate;
- said Pal and Pa2 particles being prepared according to a beading technique (nebulisation followed by cooling) well known to the person skilled in the art, in order to limit dissemination in the oral cavity of the active ingredients.
Therefore the Pa particles present very low solubility in saliva (inside the oral cavity) according to the "reference test for determining particle solubility in saliva"
defined above, so as not to cause, in particular, dissemination and coloration of the mucous membranes and the patient's mouth. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm and less than 10% are less than 125 pm.
Ps particles: The Ps particles are made up of a mixture of 70% erythritol and 28%
xylitol, and 2 % citric acid, and are obtained by mixing in solution and then drying. The particles present an apparent density of around 0.8 g.cm 3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm.
Example 5: preparation of one kilogram (1 kg) of pharmaceutical preparation based on Ibuprofen composed of a homogeneous mixture of Pa and Ps particles.
50% by weight Pa particles and 50% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 80% ibuprofen and 20%
sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the ibuprofen and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity of less than 5% of the mass of active ingredient ibuprofen is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva" defined above is applied, so as to prevent local irritation as well as a risk of absorption via the oral mucosa. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 90%
erythritol, 9%
tricalcium citrate and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva in accordance with the "reference test for determining particle solubility in saliva" defined above. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm.
Example 6: preparation of one kilogram (1 kg) of pharmaceutical preparation based on 5 ASA (5 aminosalicvlic acid) composed of a homogeneous mixture of Pa and Ps particles.
70% by weight Pa particles and 30% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 80% 5-ASA and 20% a pharmaceutical grade methacylic polymer insoluble in acid medium, and prepared according to a technique of film coating technique on a fluid air bed (FAB) well known to the person skilled in the art, in order to prevent direct contact between the 5 ASA and the patient's oral mucosa. Therefore the Pa particles present a very low solubility in saliva (inside the oral cavity) according to the "reference test for determining particle solubility in saliva" defined above, and enable a gradual release of the active substance (5ASA) into the digestive tube (colon) in order to obtain optimum efficacy.
Granulometric analysis of the Pa particles according to the sieving method shows that more than 90%
of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 90%
erythritol, 9%
tricalcium citrate and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva according to the "reference test for determining particle solubility in saliva" defined above. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm.
Example 7: preparation of one kilogram (1 kq) of food supplement based on Curcuma lonqa composed of a homogeneous mixture of Pa and Ps particles.
50% by weight Pa particles and 50% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 75% Curcuma Longa extract and 25% sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the plant extract and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity less than 5%
of the mass of the active ingredient (curcumin) is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva" defined above is applied, so as to prevent in particular coloration of the oral mucosa. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 99%
erythritol and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva"
defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 8: preparation of one kilogram (1 kg) of food supplement based on Boswellia serrata composed of a homogeneous mixture of Pa and Ps particles.
40% by weight Pa particles and 60% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 75% Boswellia serrata extract and 25% sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the plant extract and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity less than 10% of the mass of the active ingredient (Boswellic acid) is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva"
defined above is applied, so as to prevent an unpleasant sensation. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 99%
erythritol and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva"
defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 9: preparation of one kilogram (1 kq) of food supplement based on Whitania somnifera composed of a homogeneous mixture of Pa and Ps particles.
40% by weight Pa particles and 60% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 75% VVhitania somnifera extract and 25% sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the plant extract and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity less than 5% of the mass of the active ingredient (glycowithanolide) is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva"
defined above is 5 applied. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 99%
erythritol and 10 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva"
defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are 15 less than 125 pm in size.
Example 10: preparation of one kilogram (1 kg) of pharmaceutical preparation based on paracetamol composed of a homogeneous mixture of Pa and Ps particles.
20 62.5% by weight Pa particles and 37.5% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 80% paracetamol and 20%
25 sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the paracetamol and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity of less than 5% of the mass of active ingredient paracetamol is dissolved after 10 seconds when the "reference test 30 for determining particle solubility in saliva" defined above is applied, so as to prevent a risk of absorption via the oral mucosa. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 90%
erythritol, 9%
tricalcium citrate and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva according to the "reference test for determining particle solubility in saliva" defined above. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 11: Evaluation of the properties of the composition according to the invention in terms of rapidity of ingestion and ease of swallowing A study encompassing 10 subjects aged between 12 and 77 years inclusive (of which 5 women and 5 men) was conducted in order to evaluate the properties of the invention in terms of rapidity of ingestion and ease of swallowing.
The rapidity of ingestion criterion was evaluated as follows:
- A: Less than 10 seconds - B: Between 10 seconds and 20 seconds - C: Between 20 seconds and 30 seconds - D: More than 30 seconds The ease of swallowing criterion was evaluated as follows:
- 1: No difficulty in swallowing - 2: Slight discomfort in swallowing - 3: Medium discomfort in swallowing - 4: Severe discomfort in swallowing The composition described in example 1 was evaluated and table 2 below brings together the results obtained.
Subject Age Sex Ingestion Ease of time swallowing 1 24 F A (5 s) 1 2 47 M A (4 s) 1 3 35 F A (7 s) 1 4 15 M A (4 s) 1 5 68 F B (9 s) 1 6 12 F A (8 s) 1 7 77 M A (8 s) 1 8 64 M A (5 s) 1 9 33 F A (4 s) 1 10 29 M A (4 s) 1 Table 2 Results Obtained:
Ingestion time: all the subjects were able to ingest the composition according to example 1 in less than 10 seconds (of which 5 subjects in less than 5 seconds).
Ease of swallowing: all the subjects swallowed the composition very easily and did not observe any discomfort upon swallowing.
The composition according to the invention makes it possible to obtain a galenic form or packaging in the form of a mixture of particles in sachet or stick form.
Therefore the invention also relates to a dose of active ingredient in the form of the mixture described above, preferably bagged hermetically in an oblong or rectangular container, part of which can be easily torn off. Such presentations are also an object of the invention.
Advantageously, the total mass of the composition according to the invention that can be used for administering a dose of active ingredient(s) to a human being may range from 0.1 mg to 10 g, advantageously from 0.5 g to 5 g, and preferably from 1 g to 3 g.
The invention also relates to use of Ps particles such as described above for the manufacture of a composition in the form of a mixture of particles, in particular that described in the present application.
The invention also relates to the use of Pa particles such as described above for the manufacture of a composition in the form of a mixture of particles, in particular that described in the present application.
The invention also relates to a method of administering a dose of active ingredient(s) to a human or animal individual by ingestion of a mixture of particles as described in the present application. In particular, this method comprises placing the mixture of solid particles directly on the tongue. Advantageously, no additional/exogenous liquid ingestion (for example in the form of a glass of water) is required.
The invention also relates to a manufacturing method of the mixture described above.
This method comprises a step of mixing the Pa and Ps particles to obtain a homogeneous mixture of non-agglomerated solid particles. According to a preferred aspect, the Ps and Pa particles are manufactured prior to the mixing step.
Example 3: preparation of one kilogram (1 kg) of food supplement based on Tagetes erecta composed of a homo_geneous mixture of Pa and Ps particles.
20% by weight Pa particles and 80% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 40% Tagetes erecta extract (lutein), 40% microcrystalline cellulose and 20% hypromellose (hydroxypropyl methylcellulose), and prepared according to a granulation technique followed by film-coating on a fluid air bed well known to the person skilled in the art, in order to improve their stability. The Pa particles also present low solubility in saliva (in the oral cavity) according to the "reference test for determining particle solubility in saliva" defined above, so as not to cause an excessively pronounced taste in the patient's mouth.
Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% in size are less than 125 pm.
Ps particles: The Ps particles are made up of a mixture composed of 60%
sorbitol, 20%
erythritol, 18% tricalcium citrate and 2% citric acid, and are obtained by granulation and drying. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied.
Granulometric analysis of the Ps particles according to the sieving method shows that more than 90%
of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 4: preparation of one kilooram_(1 kg) of food supplement based on Chlorella and Carbo vegetalis composed of a homogeneous mixture of Pa and Ps particles.
70% by weight of a mixture of Pa particles and 30% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Mixture of Pa particles: this mixture comprises equal parts of:
- Pal particles, made up of 40% Chlorella and 60% sorbitol monostearate, and - Pa2 particles, made up of 40% Garbo vegetalis (vegetable carbon) and 60%
sorbitol monostearate;
- said Pal and Pa2 particles being prepared according to a beading technique (nebulisation followed by cooling) well known to the person skilled in the art, in order to limit dissemination in the oral cavity of the active ingredients.
Therefore the Pa particles present very low solubility in saliva (inside the oral cavity) according to the "reference test for determining particle solubility in saliva"
defined above, so as not to cause, in particular, dissemination and coloration of the mucous membranes and the patient's mouth. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm and less than 10% are less than 125 pm.
Ps particles: The Ps particles are made up of a mixture of 70% erythritol and 28%
xylitol, and 2 % citric acid, and are obtained by mixing in solution and then drying. The particles present an apparent density of around 0.8 g.cm 3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva" defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm.
Example 5: preparation of one kilogram (1 kg) of pharmaceutical preparation based on Ibuprofen composed of a homogeneous mixture of Pa and Ps particles.
50% by weight Pa particles and 50% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 80% ibuprofen and 20%
sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the ibuprofen and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity of less than 5% of the mass of active ingredient ibuprofen is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva" defined above is applied, so as to prevent local irritation as well as a risk of absorption via the oral mucosa. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 90%
erythritol, 9%
tricalcium citrate and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva in accordance with the "reference test for determining particle solubility in saliva" defined above. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm.
Example 6: preparation of one kilogram (1 kg) of pharmaceutical preparation based on 5 ASA (5 aminosalicvlic acid) composed of a homogeneous mixture of Pa and Ps particles.
70% by weight Pa particles and 30% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 80% 5-ASA and 20% a pharmaceutical grade methacylic polymer insoluble in acid medium, and prepared according to a technique of film coating technique on a fluid air bed (FAB) well known to the person skilled in the art, in order to prevent direct contact between the 5 ASA and the patient's oral mucosa. Therefore the Pa particles present a very low solubility in saliva (inside the oral cavity) according to the "reference test for determining particle solubility in saliva" defined above, and enable a gradual release of the active substance (5ASA) into the digestive tube (colon) in order to obtain optimum efficacy.
Granulometric analysis of the Pa particles according to the sieving method shows that more than 90%
of them are less than 500 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 90%
erythritol, 9%
tricalcium citrate and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva according to the "reference test for determining particle solubility in saliva" defined above. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm.
Example 7: preparation of one kilogram (1 kq) of food supplement based on Curcuma lonqa composed of a homogeneous mixture of Pa and Ps particles.
50% by weight Pa particles and 50% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 75% Curcuma Longa extract and 25% sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the plant extract and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity less than 5%
of the mass of the active ingredient (curcumin) is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva" defined above is applied, so as to prevent in particular coloration of the oral mucosa. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 99%
erythritol and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva"
defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 8: preparation of one kilogram (1 kg) of food supplement based on Boswellia serrata composed of a homogeneous mixture of Pa and Ps particles.
40% by weight Pa particles and 60% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 75% Boswellia serrata extract and 25% sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the plant extract and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity less than 10% of the mass of the active ingredient (Boswellic acid) is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva"
defined above is applied, so as to prevent an unpleasant sensation. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 99%
erythritol and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva"
defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 9: preparation of one kilogram (1 kq) of food supplement based on Whitania somnifera composed of a homogeneous mixture of Pa and Ps particles.
40% by weight Pa particles and 60% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 75% VVhitania somnifera extract and 25% sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the plant extract and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity less than 5% of the mass of the active ingredient (glycowithanolide) is dissolved after 10 seconds when the "reference test for determining particle solubility in saliva"
defined above is 5 applied. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 99%
erythritol and 10 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva - in less than 20 seconds - when the "reference test for determining particle solubility in saliva"
defined above is applied. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are 15 less than 125 pm in size.
Example 10: preparation of one kilogram (1 kg) of pharmaceutical preparation based on paracetamol composed of a homogeneous mixture of Pa and Ps particles.
20 62.5% by weight Pa particles and 37.5% by weight Ps particles are introduced into a rotary drum mixer, and are stirred for 15 minutes to form a homogenous mixture of particles.
Pa particles: The Pa particles are made up of a mixture of 80% paracetamol and 20%
25 sorbitol monostearate, and prepared according to a hot melt coating technique well known to the person skilled in the art, in order to prevent direct contact between the paracetamol and the patient's oral mucosa. Therefore the Pa particles present very low solubility in saliva (inside the oral cavity): indeed a quantity of less than 5% of the mass of active ingredient paracetamol is dissolved after 10 seconds when the "reference test 30 for determining particle solubility in saliva" defined above is applied, so as to prevent a risk of absorption via the oral mucosa. Granulometric analysis of the Pa particles according to the sieving method shows that more than 90% of them are less than pm in size and less than 10% are less than 125 pm in size.
Ps particles: The Ps particles are made up of a mixture composed of 90%
erythritol, 9%
tricalcium citrate and 1% citric acid, and are obtained by granulation. The particles present an apparent density of around 0.8 g.cm-3, and rapid solubilisation in saliva according to the "reference test for determining particle solubility in saliva" defined above. Granulometric analysis of the Ps particles according to the sieving method shows that more than 90% of them are less than 710 pm in size and less than 10% are less than 125 pm in size.
Example 11: Evaluation of the properties of the composition according to the invention in terms of rapidity of ingestion and ease of swallowing A study encompassing 10 subjects aged between 12 and 77 years inclusive (of which 5 women and 5 men) was conducted in order to evaluate the properties of the invention in terms of rapidity of ingestion and ease of swallowing.
The rapidity of ingestion criterion was evaluated as follows:
- A: Less than 10 seconds - B: Between 10 seconds and 20 seconds - C: Between 20 seconds and 30 seconds - D: More than 30 seconds The ease of swallowing criterion was evaluated as follows:
- 1: No difficulty in swallowing - 2: Slight discomfort in swallowing - 3: Medium discomfort in swallowing - 4: Severe discomfort in swallowing The composition described in example 1 was evaluated and table 2 below brings together the results obtained.
Subject Age Sex Ingestion Ease of time swallowing 1 24 F A (5 s) 1 2 47 M A (4 s) 1 3 35 F A (7 s) 1 4 15 M A (4 s) 1 5 68 F B (9 s) 1 6 12 F A (8 s) 1 7 77 M A (8 s) 1 8 64 M A (5 s) 1 9 33 F A (4 s) 1 10 29 M A (4 s) 1 Table 2 Results Obtained:
Ingestion time: all the subjects were able to ingest the composition according to example 1 in less than 10 seconds (of which 5 subjects in less than 5 seconds).
Ease of swallowing: all the subjects swallowed the composition very easily and did not observe any discomfort upon swallowing.
The composition according to the invention makes it possible to obtain a galenic form or packaging in the form of a mixture of particles in sachet or stick form.
Therefore the invention also relates to a dose of active ingredient in the form of the mixture described above, preferably bagged hermetically in an oblong or rectangular container, part of which can be easily torn off. Such presentations are also an object of the invention.
Advantageously, the total mass of the composition according to the invention that can be used for administering a dose of active ingredient(s) to a human being may range from 0.1 mg to 10 g, advantageously from 0.5 g to 5 g, and preferably from 1 g to 3 g.
The invention also relates to use of Ps particles such as described above for the manufacture of a composition in the form of a mixture of particles, in particular that described in the present application.
The invention also relates to the use of Pa particles such as described above for the manufacture of a composition in the form of a mixture of particles, in particular that described in the present application.
The invention also relates to a method of administering a dose of active ingredient(s) to a human or animal individual by ingestion of a mixture of particles as described in the present application. In particular, this method comprises placing the mixture of solid particles directly on the tongue. Advantageously, no additional/exogenous liquid ingestion (for example in the form of a glass of water) is required.
The invention also relates to a manufacturing method of the mixture described above.
This method comprises a step of mixing the Pa and Ps particles to obtain a homogeneous mixture of non-agglomerated solid particles. According to a preferred aspect, the Ps and Pa particles are manufactured prior to the mixing step.
Claims (19)
1. A solid composition with rapid ingestion and facilitated swallowing, administrable to a human or animal individual, said composition being in the form of non-agglomerated solid particles, said composition comprising the following two different types of particle:
- Pa particles, with very low solubility in saliva and comprising at least one active ingredient, in sufficient quantity to administer the desired dose of active ingredient to said human or animal individual, and - Ps particles, rapidly soluble in saliva, said Ps particles being characterised by an apparent density equal to or greater than approximately 0.6 g.cm-3, advantageously equal to or greater than approximately 0.7 g.cm-3, and preferably between 0.7 and 1.5 g.cm-3 inclusive;
said Ps particles being present in said composition in sufficient quantity to enable rapid ingestion and facilitated swallowing of said Pa particles in said human or animal individual.
- Pa particles, with very low solubility in saliva and comprising at least one active ingredient, in sufficient quantity to administer the desired dose of active ingredient to said human or animal individual, and - Ps particles, rapidly soluble in saliva, said Ps particles being characterised by an apparent density equal to or greater than approximately 0.6 g.cm-3, advantageously equal to or greater than approximately 0.7 g.cm-3, and preferably between 0.7 and 1.5 g.cm-3 inclusive;
said Ps particles being present in said composition in sufficient quantity to enable rapid ingestion and facilitated swallowing of said Pa particles in said human or animal individual.
2. The composition according to the previous claim, comprising a homogeneous mixture of Pa and Ps particles.
3. The composition according to claim 1 or 2, said composition being a homogenous mixture of non-agglomerated solid particles, suitable for being packed in sachets and/or in sticks, preferably in single-dose sachets and/or sticks.
4. The composition according to one of the previous claims, wherein the Ps particles comprise at least one polyol with low glycaemic index, such as erythritol, preferably in a mass percentage representing at least 50% of the total mass of the Ps particles.
5. The composition according to the previous claim, wherein the Ps particles also comprise at least one natural organic acid, or a salt thereof, preferably a metabolically non-acidifying natural organic acid, such as citric acid and/or a salt thereof, such as calcium citrate or magnesium citrate.
6. The composition according to the previous claim, wherein said at least one natural organic acid, or a salt thereof, is present in the Ps particles in a mass percentage not exceeding 50% of the total mass of the Ps particles.
7. The composition according to claim 5 or 6, wherein the weight ratio of natural organic acid(s) (or a salt (salts) thereof) / polyol(s) with low glycaemic index is between 0.01 and 1 inclusive.
8. The composition according to one of the previous claims, wherein the Ps particles have an average size less than or equal to approximately 500 µm; preferably said Ps particles have a size range of between approximately 50 µm and approximately 500 µm, preferably between approximately 100 µm and approximately 500 µm, advantageously between approximately 200 µm and approximately 400 µm.
9. The composition according to one of the previous claims, wherein the Ps particles are free from disintegrating agents such as a cross-linked polyvinylpyrrolidone, a cross-linked carboxymethyl cellulose and/or hydroxypropyl cellulose.
10. The composition according to one of the previous claims, wherein the Pa particles are made up of or are coated with a hydrophobic material in order to:
- protect them from moisture and/or limit their solubility in saliva, and/or - modulate the release of at least one active ingredient contained therein in one or more parts of the digestive tract.
- protect them from moisture and/or limit their solubility in saliva, and/or - modulate the release of at least one active ingredient contained therein in one or more parts of the digestive tract.
11. The composition according to one of the previous claims, wherein the Pa particles have an average size of less than approximately 500 µm; preferably said Pa particles have a size range of between approximately 50 µm and approximately 500 µm, advantageously between approximately 100 µm and approximately 400 µm.
12. The composition according to one of the previous claims, wherein the average size of the Ps particles and the average size of the Pa particles are no more than 50%, and preferably no more than 25%, different from each other.
13. The composition according to one of the previous claims, said composition being free from disintegrating agents such as a cross-linked polyvinylpyrrolidone and/or a cross-linked carboxymethyl cellulose.
14. The composition according to one of the previous claims, wherein the ratio between the mass of Pa particles and the mass of Ps particles is less than 10, preferably less than 5, advantageously less than or equal to 4, preferably less than or equal to 3, and particularly preferably less than or equal to 2.5.
15. The composition according to the previous claim, wherein said ratio is less than or equal to 1, preferably less than or equal to 0.75 and advantageously less than or equal to 0.5.
16. A medicine with rapid ingestion and facilitated swallowing or food supplement with rapid ingestion and facilitated swallowing, for human or animal use, comprising the composition according to one of the previous claims.
17. A sachet or stick, preferably hermetically sealed, comprising:
- the composition according to one of claims 1 to 15, or - the medicine with rapid ingestion and facilitated swallowing or the food supplement with rapid ingestion and facilitated swallowing according to claim 16.
- the composition according to one of claims 1 to 15, or - the medicine with rapid ingestion and facilitated swallowing or the food supplement with rapid ingestion and facilitated swallowing according to claim 16.
18. Use of a composition according to one of claims 1 to 15 for the preparation of a medicine with rapid ingestion and facilitated swallowing or a food supplement with rapid ingestion and facilitated swallowing, for human or animal use.
19. Ps particles as defined in one of claims 1 to 9.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1658666 | 2016-09-15 | ||
FR1658666A FR3055800B1 (en) | 2016-09-15 | 2016-09-15 | SOLID COMPOSITION WITH FAST INGESTION AND EASY SWALLOWING, IN THE FORM OF NON-AGGLOMERATED SOLID PARTICLES, COMPRISING TWO DIFFERENT TYPES OF PARTICLES |
PCT/FR2017/052476 WO2018051039A1 (en) | 2016-09-15 | 2017-09-15 | Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3036646A1 true CA3036646A1 (en) | 2018-03-22 |
Family
ID=57348953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3036646A Pending CA3036646A1 (en) | 2016-09-15 | 2017-09-15 | Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles |
Country Status (16)
Country | Link |
---|---|
US (1) | US11304905B2 (en) |
EP (1) | EP3512497A1 (en) |
JP (1) | JP7035020B2 (en) |
KR (2) | KR20190067791A (en) |
CN (1) | CN109963554A (en) |
AU (1) | AU2017327889B2 (en) |
BR (1) | BR112019005076A2 (en) |
CA (1) | CA3036646A1 (en) |
CO (1) | CO2019003705A2 (en) |
FR (1) | FR3055800B1 (en) |
MA (1) | MA46238A (en) |
PH (1) | PH12019500473A1 (en) |
RU (1) | RU2019106169A (en) |
SA (1) | SA519401236B1 (en) |
WO (1) | WO2018051039A1 (en) |
ZA (1) | ZA201901907B (en) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
IT1270594B (en) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
CN1155242A (en) * | 1994-07-07 | 1997-07-23 | 雷科达逖化学制药公司 | Liquid pharmaceutical composition for controlled release of moguisteine |
JP2000516222A (en) | 1996-08-15 | 2000-12-05 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテル ハフツング | Oral pharmaceutical composition that is easy to swallow |
TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
JP4358920B2 (en) | 1998-10-07 | 2009-11-04 | 興和創薬株式会社 | Erythritol-containing spherical granules and method for producing the same |
FR2785538B1 (en) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
JP2001064159A (en) | 1999-08-25 | 2001-03-13 | Shionogi & Co Ltd | Composite granular preparation |
FR2816840B1 (en) * | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | MEDICINE BASED ON SUSTAINED RELEASE ANTI-HYPERCLYCEMIA MICROCAPSULES AND METHOD FOR PREPARING THE SAME |
FR2830447B1 (en) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS |
ES2409347T3 (en) | 2004-10-21 | 2013-06-26 | Aptalis Pharmatech, Inc. | Pharmaceutical compositions of masked flavor with gastro-soluble porogenic agents |
US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
EP1905428A1 (en) | 2006-09-26 | 2008-04-02 | Losan Pharma GmbH | Ibuprofen efferscent tablet with dissolution rate and process for preparation |
JP5258268B2 (en) | 2007-11-19 | 2013-08-07 | フロイント産業株式会社 | Method for producing spherical particles |
PL3345625T3 (en) | 2008-08-13 | 2021-06-14 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
AR073651A1 (en) * | 2008-09-24 | 2010-11-24 | Novartis Ag | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS |
WO2011112771A1 (en) * | 2010-03-11 | 2011-09-15 | Rich Vitamins Llc | Quick dissolve nutritional powder |
JP2012246252A (en) | 2011-05-27 | 2012-12-13 | Bayer Yakuhin Ltd | Modified-release type particle pharmaceutical composition for oral administration, method for producing the same, and orally disintegrating tablet including the composition |
-
2016
- 2016-09-15 FR FR1658666A patent/FR3055800B1/en active Active
-
2017
- 2017-09-15 RU RU2019106169A patent/RU2019106169A/en unknown
- 2017-09-15 MA MA046238A patent/MA46238A/en unknown
- 2017-09-15 KR KR1020197010066A patent/KR20190067791A/en not_active IP Right Cessation
- 2017-09-15 CA CA3036646A patent/CA3036646A1/en active Pending
- 2017-09-15 EP EP17780482.0A patent/EP3512497A1/en active Pending
- 2017-09-15 US US16/330,288 patent/US11304905B2/en active Active
- 2017-09-15 AU AU2017327889A patent/AU2017327889B2/en active Active
- 2017-09-15 JP JP2019510687A patent/JP7035020B2/en active Active
- 2017-09-15 CN CN201780070952.2A patent/CN109963554A/en active Pending
- 2017-09-15 KR KR1020227014336A patent/KR102486095B1/en active IP Right Grant
- 2017-09-15 WO PCT/FR2017/052476 patent/WO2018051039A1/en unknown
- 2017-09-15 BR BR112019005076A patent/BR112019005076A2/en active Search and Examination
-
2019
- 2019-03-04 PH PH12019500473A patent/PH12019500473A1/en unknown
- 2019-03-05 SA SA519401236A patent/SA519401236B1/en unknown
- 2019-03-27 ZA ZA2019/01907A patent/ZA201901907B/en unknown
- 2019-04-12 CO CONC2019/0003705A patent/CO2019003705A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
FR3055800B1 (en) | 2020-06-26 |
US11304905B2 (en) | 2022-04-19 |
CN109963554A (en) | 2019-07-02 |
MA46238A (en) | 2019-07-24 |
SA519401236B1 (en) | 2023-02-15 |
KR102486095B1 (en) | 2023-01-09 |
BR112019005076A2 (en) | 2019-06-04 |
JP7035020B2 (en) | 2022-03-14 |
RU2019106169A (en) | 2020-10-15 |
US20190201343A1 (en) | 2019-07-04 |
AU2017327889B2 (en) | 2023-04-13 |
FR3055800A1 (en) | 2018-03-16 |
WO2018051039A1 (en) | 2018-03-22 |
CO2019003705A2 (en) | 2019-05-21 |
EP3512497A1 (en) | 2019-07-24 |
RU2019106169A3 (en) | 2020-10-15 |
JP2019534239A (en) | 2019-11-28 |
PH12019500473A1 (en) | 2019-07-24 |
KR20190067791A (en) | 2019-06-17 |
ZA201901907B (en) | 2020-10-28 |
KR20220062665A (en) | 2022-05-17 |
AU2017327889A1 (en) | 2019-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fini et al. | Fast dispersible/slow releasing ibuprofen tablets | |
EP2654735B1 (en) | Rapidly disintegrating, solid coated dosage form | |
TWI695722B (en) | Solid preparation outer layer composition and easy-to-take solid preparation containing the outer layer composition | |
JP2023164934A (en) | Solid pharmaceutical | |
CN108348616A (en) | Easy taking solid pharmaceutical preparation particulate composition and the easy taking solid pharmaceutical preparation comprising the particulate composition | |
US8715729B2 (en) | Rapidly disintegrating, solid coated dosage form | |
Dash | Solid dosage forms | |
JP3230457U (en) | Tablets containing turmeric | |
AU2017327889B2 (en) | Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles | |
TWI690333B (en) | Manufacturing method of easy-to-take solid preparation (with nuclear ingot) and easy-to-take solid preparation | |
JP2002255797A (en) | Mold tablet | |
Patil et al. | Formulation and Evaluation of Mouth Dissolving Tablet | |
Pingale et al. | Formulation and evaluation of fast disintegrating tablet of eletriptan hydrobromide | |
Gillani et al. | Vitamin C and cranberry extract effervescent tablet formulation, characterization, and evaluation | |
JP7133982B2 (en) | tablet composition | |
Ouédraogo et al. | Formulation and evaluation of granules based on trunks barks extracts of Anogeissus leiocarpus (DC) Guill. et Perr.(Combretaceae) intended for the development of phytomedicines for the treatment of hypertension | |
TWI703989B (en) | Oral retention type disintegrating solid preparation, its manufacturing method, and powder composition used in the manufacturing method | |
Bhesaniya et al. | ORODISPERSIBLE MINI-TABLETS: A REVIEW. | |
CN107708648B (en) | Method for producing easily administrable solid preparation and easily administrable solid preparation | |
TWI406679B (en) | Oral disintegrating tablet containing a high dosage of active ingredients | |
FR3095762A1 (en) | Solid composition for rapid ingestion and easy swallowing, in the form of non-agglomerated solid particles, comprising two different types of particles | |
JP2021187856A (en) | Compressed solid composition | |
Patel et al. | A Current Review on Orodispersible Tablet | |
WO2017078557A1 (en) | Preparing a tablet with a mechanism for enhancing the therapeutic effectiveness of a drug using a nano-dose of an analogue | |
Patil Vaishali et al. | Vaishali et al. World Journal of Pharmaceutical Research |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220627 |
|
EEER | Examination request |
Effective date: 20220627 |
|
EEER | Examination request |
Effective date: 20220627 |
|
EEER | Examination request |
Effective date: 20220627 |
|
EEER | Examination request |
Effective date: 20220627 |
|
EEER | Examination request |
Effective date: 20220627 |